



SBI Holdings, Inc. FY2016 Financial Results

(Fiscal Year Ended March 31, 2017)

April 28, 2017



The items in this document are provided as information related to the financial results and the business strategy of the SBI Group companies and not as an invitation to invest in the stock or securities issued by each company.

None of the Group companies guarantees the completeness of this document in terms of information and future business strategy.

The content of this document is subject to revision or cancellation without warning.

Note: Fiscal Year ("FY") ends March 31 of the following year



- 1. FY2016 consolidated financial results, and a summary of the past five years
- 2. Basic strategy for the next three years based on the summary of the past five years



1. FY2016 consolidated financial results, and a summary of the past five years



[FY2016 consolidated financial results]

-Highlights of the consolidated financial results-

- FY2016 revenue achieved historical high
- While the individual stock brokerage trading value floundered after peaking in FY2013, the Company continuously recorded profit attributable to owners of the Company of over JPY 30bn for three consecutive fiscal years from FY2014, improving its resistance to stock market declines
- Continued high level shareholder returns, as reflected by the increase in dividends linked to profits, for four consecutive fiscal years






[Year-on-year] (Unit: JPY million)

	FY2015 (Apr. 2015 - Mar. 2016)	FY2016 (Apr. 2016 - Mar. 2017)	YoY % change
Revenue	261,744	261,939 Historical high	+0.1
Profit before income tax expense	52,227	43,139	-17.4
Profit for the period	36,666	28,303	-22.8
Profit attributable to owners of the Company	34,115	32,455	-4.9
ROE (%)	9.0	8.7	-0.3pt




Consolidated Financial Results for the Past Five Fiscal Years (IFRS) [Revenue]






Consolidated Financial Results for the Past Five Fiscal Years (IFRS) [Profit attributable to owners of the Company]





Changes in ROE



In FY2016, Continued to Conduct Active Shareholder Returns Initiated from the Previous FY2015

[Basic policy for shareholder return]

Conduct shareholder returns with a target of achieving a total shareholder return ratio, as calculated by the sum of dividend payouts and share repurchase costs, of 40% as a minimum

Dividend forecast (result) per share

	End of 2Q	Year-end	Full-year
FY2016 (forecast)	<u>JPY 10</u>	<u>JPY 40</u>	<u>JPY 50</u>
FY2015 (result)	JPY 10	JPY 35	JPY 45

Share repurchase

Implemented a share repurchase of approx. JPY 8.0bn, during Aug. 3 to Sept. 5, 2016, of SBI shares




Shareholder Return Results for the Past Five Fiscal Years

		FY2012	FY2013	FY2014	FY2015	FY2016
Dividond	Full-year dividend per share	JPY 10	JPY 20	JPY 35	JPY 45	JPY 50
Dividend	Sum of dividend payouts (JPY bn)	2.2	4.3	7.6	9.4	10.2
	repurchase nt (JPY bn)	_		10.0	5.0	8.0
	reholder return nt (JPY bn)	2.2	4.3	17.6	14.4	18.2
	eholder return tio (%)	56.9	20.2	38.5	42.2	55.9



SBI Holdings' Shareholder Composition

- The total number of shareholders is 133,067, of which the number of shareholders who hold 1 unit or more is 80,290
- Shareholding ratio of domestic and foreign institutional investors is 63.0%, and the <u>substantive shareholding ratio of domestic and foreign institutional investors</u>, excluding treasury stock, is at 69.5%





[Segment overview] -FY2016 segment result highlights-

- In the Financial Services Business, owing to the increase in the FX and insurance businesses' financial results, FY2016 profit before income tax expense declined by only 3.8% year-on-year, despite the fact that the individual stock brokerage trading value declined by 16.4% year-on-year. On the other hand, as both businesses continued to expand, revenue increased by 6.5% year-on-year, achieving a record high
- In the Asset Management Business, despite adverse factors such as a sluggish stock market and yen appreciation trend, SBI SAVINGS BANK of South Korea established a stable revenue base, owing to a significant accumulation of performing loans balance, to support the entire segment's results
- In the Biotechnology-related Business, the losses widened, owing to an increase in cost due to the steady progress in multiple clinical trials at Quark, including two Phase III pipeline drugs.
 - On the other hand, <u>owing to milestone payments and out-licensing</u> <u>revenues</u>, <u>both SBI Biotech and SBI Pharmaceuticals achieved their first full-year profitability since their establishment</u>



FY2016 Revenue by Segment (IFRS)

[Year-on-year] (Unit: JPY million)

	FY2015 (Apr. 2015 - Mar. 2016)	FY2016 (Apr. 2016 - Mar. 2017)	YoY % change
Financial Services Business	166,208	176,989 Historical high	+6.5
Asset Management Business	91,543	80,392	-12.2
Biotechnology- related Business	4,021	5,530	+37.5

^{*} Figures are before elimination of the inter-segment transactions.



FY2016 Profit before Income Tax Expense by Segment (IFRS)


[Year-on-year] (Unit: JPY million)

	FY2015 (Apr. 2015 - Mar. 2016)	FY2016 (Apr. 2016 - Mar. 2017)	YoY change (% change / amount)
Financial Services Business	50,806	48,853	-3.8%
Asset Management Business	17,649	13,940	-21.0%
Biotechnology- related Business	-6,572	-9,574	-3,002

^{*} Figures are before elimination of the inter-segment transactions.

SBI Holdings

Segment Performance Trend (IFRS)



^{*} Abovementioned figures are before elimination of the inter-segment transactions. Also, since there are Group companies that have been transferred from one segment to an another, the abovementioned figures reflect disclosed figures during each fiscal year, therefore, there may be some discrepancies




(1) Financial Services Business

- In order to shift to an earnings structure that is more resistant to a recessionary environment in a declining stock market phase, a steady business diversification was promoted for the past 10 years
- Other non-securities financial services businesses, including banking, insurance and FX have steadily grown
- With the exception of subsidiaries that have been established within the past two years, all of the companies have achieved profitability and have further strengthened their profit growth trend



The SBI Group's Business Portfolio Diversification Progression

3 Market total (Tokyo, Osaka, Nagoya), semiannual individual stock



^{*} Japanese stocks listed on Tokyo Stock Exchange, Osaka Stock Exchange and Nagoya Stock Exchange (Including TSE Mothers, JASDAQ and NSE Centrex)

Source: Complied by SBIH from disclosed data from TSE

-Major initiatives implemented in the Financial Services Business-

Sept. 2007	Launch of SBI Sumishin Net Bank	Aug. 2014	Sold former SBI Mortgage
Jan. 2008	Launch of SBI Insurance	Feb. 2015	Acquired current SBI Life Insurance
Nov. 2008	Launch of SBI Liquidity Market	July 2015	Established SBI BITS
May 2012	Launch of SBI FXTRADE	Feb. 2016	Started new sales at SBI Life Insurance
June 2012	Launch of SBI MONEY PLAZA	May 2016	Established SBI Ripple Asia
Mar. 2013	Acquired current SBI IKIIKI SSI	Sept. 2016	Acquired Nihon SSI
		Nov. 2016	Established SBI Virtual Currencies

Other Non-securities Financial Services Businesses, Florings Including Banking, Insurance and FX have Steadily Grown

<u>Profit before income tax expense of major Financial</u> Services Business companies (IFRS)

(JPY million)

	FY2012	FY2013	FY2014	FY2015	FY2016
SBI SECURITIES (non-cons.)	11,623	33,344	34,828	37,850	33,043
FX business (SBI LM, SBI FXT)	1,369	3,160	4,741	5,200	5,734
SBI Sumishin Net Bank*	1,622	2,062	5,196	3,385	3,185
Net profit based on J-GAAP	4,779	7,116	9,998	8,413	N/A until May 12
Insurance business	-5,105	-3,601	28	265	1,920

[Total loss amount incurred by unprofitable subsidiaries (excluding those established within the past 2 years)]

(JPY billion)

	FY2012	FY2013	FY2014	FY2015	FY2016
Total loss amount	-8.9	-9.2	-3.0	-1.1	0.0

SBI FXT: Full-year profitability

SBI Card: Disposal

SBI Insurance, SBI Remit: Full-year profitability

SBI Social Lending: Full-year profitability

^{*} Presents equity in earnings of affiliates.



1 Securities-related business

- Despite the fact that the individual stock brokerage trading value of the Tokyo and Nagoya stock markets decreased 16.4% year-on-year, SBI SECURITIES' commissions decreased by only 9.0% year-on-year.
 - FY2016 operating revenue achieved an historical high of JPY 90.5bn. Moreover, profit attributable to owners of the Company for FY2016 decreased by only 1.0% year-on-year, owing to a favorable increase in trading gains
- Compared to that of five fiscal years ago, profit from other than flow-type business was successfully expanded, owing to the diversification of profit-making sources. <u>As the dependence on</u> <u>stock brokerage commissions declined, sustained a strong</u> <u>profit level in spite of adverse business conditions</u>
- In the retail business, focused on the expansion of NISA and iDeCo businesses, as the government strongly supports the acceleration of the flow "from savings to asset formation"








- Expands the corporate business through the <u>enhancement of</u> the equity and bond underwriting businesses, as well as expansion of businesses with financial institutions
- SBI Liquidity Market's <u>operating income before allocation</u> for FY2016 was <u>approx. JPY 13.0bn</u>, <u>up 3.9% year-on-year</u>, recording a <u>historical high</u>
- Along with the SBI SECURITIES' number of accounts, customers' deposit assets and the share of individual stock brokerage trading value, the Group's FX trading accounts and deposit assets ranked No. 1 in the industry as well, overwhelmingly surpassing its competitors
- SBI Japannext <u>promotes efforts to improve convenience of PTS transactions</u>, including margin trading through PTS




SBI SECURITIES' Financial Results (J-GAAP)



Changes in SBI SECURITIES' Operating Revenue Structure

Owing to the diversification of its earnings sources, dependence on stock brokerage commissions declined, and <u>businesses other than stock brokerage</u> commissions, such as financial revenues and trading gains/losses have expanded





Comparison of Major Securities Companies' Net Income (J-GAAP; YoY)

[Year-on-year]

(Unit: JPY million)

		FY2015 (Apr. 2015 – Mar. 2016)	FY2016 (Apr. 2016 – Mar. 2017)	YoY % change
0	SBI (cons.)	28,087	27,798	-1.0
Online	Monex *1 (cons.)	3,554	298	-91.6
	Rakuten *2 (cons.)	15,299	12,010	-21.5
securities	Matsui	14,763	10,697	-27.5
S	kabu.com	8,016	6,006	-25.1
Fac	Nomura *3 (cons.)	131,550	239,617	+82.1
Face-to-face	Daiwa (cons.)	116,848	104,067	-10.9
face	SMBC Nikko (cons.)	42,106	46,943	+11.5


^{*1} Since Monex adopts IFRS, the relevant figures above are based on IFRS, presenting the "Profit attributable to owners of the Company" disclosed by Monex.

^{*2} Rakuten disclosed its financial results for FY2015 on a non-consolidated basis; therefore the figure for FY2015 and the year-on-year change are based on the corresponding figure.

^{*3} Figures for Nomura are based on US-GAAP, presenting the "Profit attributable to owners of the Company"



Net Income of SBI SECURITIES and 5 Online Securities Companies based on J-GAAP (FY2012 - FY2016)




^{*1} Since Monex adopts IFRS, the relevant figures above are based on IFRS, presenting the "Profit attributable to owners of the Company" disclosed by Monex.

^{*2} Rakuten disclosed its financial results for FY2015 on a non-consolidated basis; therefore the figure for FY2015 is based on the corresponding figure.

Source: Compiled by SBIH from the information on the website of each company






^{*} Rakuten has not disclosed its figures beyond Sept. 30, 2016. Source: Compiled by SBIH from the information on websites of each company.




Online Securities Companies' Share of Individual Stock Trading Value



^{*} Shares are calculated by dividing each company's individual stock trading value or individual margin trading value with the whole individual stock trading value and individual margin trading value of the 1st and 2nd section of the Tokyo and Nagoya Stock Exchange, including that of ETF and REIT trading value, respectively


Number of Accounts have Reached a Level that is Competitive with Major Face-to-face Securities Companies

Is it possible to overtake Daiwa's number of brokerage accounts within FY2017?






SBI SECURUITIES' Interest Credit Balance



SBI SECURITIES' Investment Trust Balance and the Change in Total Periodic Investment Trust Setting Amount






Succeeded in Acquiring New Customers for NISA, and Continues a Steady Increase

(Mar. 2017)	SBI*1	kabu.com	Matsui ∗1	Nomura *1	Daiwa
No. of NISA accounts *2	970,000	140,000	120,000	1,750,000	780,000

^{*1} Includes the number of Junior NISA accounts *2 Amounts are rounded to the nearest JPY 10 thousand.

SBI SECURITIES' number of Junior NISA accounts reached 26 thousand accounts as of Mar. 2017, accounting for approx. 30% of Japan's entire Junior NISA accounts

Comparison of NISA's Customer Attributes



■ Active account ratio of 65.3% (Among the entire securities industry, the ratio is 60.7%)

Source: JSDA

^{*3} The number of accounts are as of the end of Mar. 2017, compiled by SBIH from the information on website of each company



Further Strengthen the iDeCo Business, which is Expected to Substantively Promote a Flow from Savings to Asset Formation

In the full-fledged flow "from savings to asset formation," endeavors to further expand the Japanese iDeCo market, whose <u>market size is expected to reach approx. JPY 6tn in the next ten year period from approx. JPY 1.2tn as of the end of Mar. 2016,</u> by offering products with high customer benefits, and through the <u>integration of the management resources of the Daiwa Securities Group and the SBI Group</u>



Track record as the industry's largest company in the acquisition of new iDeCo customers

Establishment of partnership



Daiwa Securities Group


- Know-how as a face-to-face general securities firm
- Broad sales structure centering on face-to-face shops across the nation

[Content of the alliance]

- ✓ From Apr. 2017, <u>launched a new iDeCo plan</u> for Daiwa Securities' customers with SBI Benefit Systems as the record keeping institution
- ✓ <u>Daiwa Securities Group acquired 33.4%</u> of SBI Benefit System's shares



The targeted group was <u>expanded to all active generations</u> who have joined the National Pension Plan, since 2017, resulting in an expectation of a significantly expanded market size



^{*} Cumulative total number of new subscribers and transfers announced by the National Pension Fund Association, which include overlapping persons who has newly subscribed and also transferred to iDeCo.

Source: Briefing paper of the National Pension Fund Association (partially includes estimates by SBI)



SBI SECURITIES is an Industry Leader in Terms of the Number of IPOs Underwritten

Endeavoring to expand the corporate business by continuing to expand the IPO and PO underwriting businesses

Number of IPOs Underwritten by SBI SECURITIES (No. of companies) Continuously focusing on IPO underwriting 90 82 77 80 73 Ranked No. 4 in the industry for lead underwriting 13 70 companies in FY 2016 For FY2017, targeting lead 60 underwriting of 20 companies 50 42 42 40 26 30 20 14 10 0 FY2016 FY2010 FY2011 FY2013 FY2014 FY2015 Lead 8 5 5 8 underwriting

IPO Underwriting Ranking (Apr. 2016 - Mar. 2017)
87 companies were listed during the period

Company name	No. of cases	Underwriting share (%)
SBI	77	88.5
SMBC Nikko	71	81.6
Mizuho	55	63.2
Monex	40	46.0
Daiwa	37	42.5
Nomura	32	36.8

^{*} The above figures do not include consignments, and is based on listing dates. The figures exclude brokerage sales and REITs.

^{*} The number of IPOs does not include issues listed on TOKYOAIM.

^{*} The above IPOs represent issues underwritten in Japan only and do not include additional secondary offerings or overseas issues.

^{*} The number of underwritten issues represents both lead managed underwritings and syndicate participation.

^{*} The data was compiled by SBIH based on each company's published information.

Advancing Business Expansion with Financial Institutions through Strengthened Cooperation with SBI Investment and SBI SECURITIES' Financial Institutional Sales Dept.

By thoroughly utilizing the Group's network, strengthening the sales of products, such as structured bonds, domestic and overseas bonds toward financial institutions partners, who are FinTech Fund and SBI Regional Bank Value Creation Fund's equity investors, as well as investee regional financial institutions



Financial Institutional Sales Dept.



Distribution of structured bonds. domestic and overseas bonds. as well as investment trusts

Financial Institutions



SBI Group's regional financial institution partners, equity investors of the Group's funds, etc.

SBI SECURITIES has been promoting self-origination of structured bonds, and in 2016, originated and distributed a total amount of JPY 6.5bn

[Specific examples]

- Started providing financial instruments intermediary services with The Shimizu Bank, from Mar. 2017 This is SBI SECURITIES' first alliance case with a regional bank for intermediary brokerage services, and through further alliances with other regional banks, will proactively develop regional customers
- Distributes domestic and overseas bonds and investment trusts to multiple financial institutions, with a focus on regional financial institutions

① Securities-related business: SBI Liquidity Market, SBI FXTRADE




SBI Liquidity Market's Operating Income Before Allocation Achieved Record High (Unit: JPY million)

	Establish- ment	Number of accounts	Deposits (JPY billion)
SBI Group *1	Nov. 2008 [SBI LM]	905,585 (Mar. 2017)	171.4 (Mar. 2017)
(SBI FXT)	May 2012	186,275 (Mar. 2017)	37.0 (Mar. 2017)

Operating income (J-GAAP)		YoY %
FY2015	FY2016	change
12,520	13,007	+3.9
1,892	2,609	+37.9

Change of the SBI Liquidity Market's operating income before allocation *2



^{*1} Operating income of the SBI Group is SBI Liquidity Market's operating income before allocation which represents the amount before its allocation of profits to affiliated companies: SBI SECURITIES, SBI Sumishin Net Bank and SBI FXTRADE

^{*2} Operating income before allocation of the SBI Liquidity Market is operating income before allocation which represents the amount before its allocation of profits to affiliated companies: SBI SECURITIES, SBI Sumishin Net Bank and SBI FXTRADE

① Securities-related business: SBI Liquidity Market, SBI FXTRADE

The SBI Group's (SBI SECURITIES, SBI FXTRADE and SBI Sumishin Net Bank) Total SBI Number of Accounts and Customer Deposit Assets have Overwhelmingly Surpassed that of Its Competitors in the OTC FX Industry

Changes in number of accounts among (Thousand **5 major FX Trading Companies** accounts) (Apr. 2015 - Mar. 2017)*

SBI Group 900 800 700 600 DMM.com **GMO CLICK** 500 400 Gaitame.com 300 200 Apr. Oct. 2017

Customers' Deposit Assets Raking (Mar. 2017)*

No.	Company name	Amount (JPY million)
1	SBI Group	171,373
2	GMO CLICK	120,687
3	Gaitame.com	111,264
4	DMM.com	99,630
5	YJFX	93,606
6	Central Tanshi FX	61,284
7	MONEY PARTNERS	60,814
8	Hirose FX	38,708
9	FX PRIME by GMO Corporation	15,830
10	Traders Securities	12,172
11	Ueda Harlow	11,422
	Others (2 companies)	11,867
	Total	810,901

^{*} The number of accounts and customer deposit assets, excluding the SBI Group, are as of Feb. 2016, based on Yano Research "Monthly Research on 16 Major FX Trading Companies



SBI Japannext Promotes Efforts to Improve Convenience of PTS Transactions



- ► The only PTS operator that provides daytime and nighttime trading in the Japanese stock market.
- SBI Japannext ◆ The number of participating transaction securities companies totaled 30 (as of Mar. 31, 2017)
- > Extended nighttime trading session from Feb. 1, 2017, by moving the starting time forward from 7pm to 4:30pm
- In preparations for the trading of <u>Japanese government bonds on the</u> proprietary trading system (PTS) for overseas market makers and major brokers, having received an approval from the relevant authorities on Apr. 5, 2017, for the commencement of services planned by Sept. 2017

Lifting of the Prohibition on Margin Trading of Stocks on PTS

- ✓ A policy of permitting margin trading on the PTS was articulated by the Financial System. Council's Working Group on Financial Markets in a report issued in Dec. 2016.
- The Working Group on PTS Margin Trading of the Japan Securities Dealers Association is discussing making preparations for off-exchange investor-focused margin trading
- In addition to the existing participating securities companies, requests from multiple other online securities companies to connect to the PTS were received, resulting in a total of over 30 companies expected to connect to the PTS for the margin trading of stocks



② Banking-related business


- SBI Holdings' equity in earnings of SBI Sumishin Net Bank based on IFRS for FY2016 was JPY 3,185m
 * SBI Sumishin Net Bank's J-GAAP based FY2016 financial
 - * SBI Sumishin Net Bank's J-GAAP based FY2016 financia results is schedule to be announced on May 12, 2017
- As of the end of Mar. 2017, <u>accounts steadily increased to approx. 2.83 million accounts, with deposits exceeding JPY 4.0tn, overwhelmingly surpassing its competitors</u>

② Banking-related business: SBI Sumishin Net Bank



Change in SBI Sumishin Net Bank's Financial Results (J-GAAP)

-FY2016 financial results announcement is scheduled on May 12, 2017-




SBI Holdings' equity in earnings of SBI Sumishin Net Bank based on IFRS for FY2016 was JPY 3,185m

Note: Owing to the difference in IFRS and J-GAAP for asset assessment criteria, the figures differ from that disclosed based on J-GAAP.

SBI Sumishin Net Bank's Customer Base is Increasing at an Accelerated Pace



Pure-play Internet Banks' Deposits Since Establishment (*)




^{*} Compiled by SBIH from the published materials of the noted banks, with each origin denoting the earliest available data of deposit balance amount, since the establishment of the respective banks. The deposit balance amount of 3 banks excluding SBI Sumishin Net Bank, Daiwa Next Bank and Jibun Bank are as of the end of Dec. 2016.



Diversification of Loans with Deposits Accumulating

Change in Balance of Housing Loans *1



SBI Sumishin Net Bank's housing loans business:


- 1 Housing loans processed directly by SBI Sumishin Net Bank
 - Via alliance with real estate companies (from Sept. 2007)
 - Banking agency specialized product "MR. Housing Loan REAL" (from Mar. 2015)
- ② Banking agency business for Sumitomo Mitsui Trust Bank "Internet Exclusive Housing Loan" (from Jan. 2012)
- ③ Long-term fixed rate product "Flat 35" (from Sept. 2015)

Further improved customer convenience with the launch of the Internet conclusion type application service for group credit life insurance directed to "Internet Exclusive Housing Loan" applicants in June 2016

2 Banking-related business: SBI Sumishin Net Bank




Cumulative Total of Housing Loans has Rapidly Increased, Owing to Attractive Interest Rates and Highly Beneficial **Customer Services**





Change in the Balance of Card Loans

(Sept. 2010 - Mar. 2017)






③ Insurance-related business

- SBI Insurance's profit before income tax expense improved by more than JPY 5bn (IFRS basis), from a deficit record in fiscal year five years ago.
 Both the number of contracts and direct premiums written maintained a double digit growth, as well as a profitable trend, even accounting for the reasonable premium reserves
- The combined ratio (underwriting basis) of SBI Insurance declined by 4.4 percentage points year-to-year to 91.2%
- Upon SBI Life Insurance's consolidation as a subsidiary, despite factors such as the added cost of new product sales, owing to the results of cost reduction and stable operations, a steady business performance resulted
- Small-amount, short-term insurance business has <u>steadily</u> increased its number of contracts after acquisition



SBI Insurance Financial Results for Five Fiscal Years Holdings



Combined ratio (based on direct figures)

(Unit: %)	FY2012	FY2013	FY2014	FY2015	FY2016
Loss ratio*1	73.6	74.1	76.1	74.7	<u>71.8</u>
Operating expenses ratio*2	29.3	26.2	23.3	20.8	<u>19.4</u>
Combined ratio	102.8	100.3	99.4	95.6	91.2


^{*1} Loss ratio (%) = (Direct net insurance payment + Loss adjustment expenses) / Direct premium written X 100

^{*2} Operating expenses ratio (%) = (Operating expenses except for reinsurance commissions) / Direct premium written X 100

^{*3} Percentages in the table above are based on direct figures



SBI Insurance's Number of Auto Insurance Contracts and Insurance Premium



^{*} Includes new contracts that were paid by the end of the month, but becomes effective the following month or later

Comparison of Auto Insurance Premiums among Direct Holdings Insurance Companies

[Auto insurance premium comparison]

(JPY million)

	Date of operation started	FY2009
Sony Assurance	Sept. 1999	59,849
AXA GENERAL INSURANCE	July 1999	32,054
Mitsui Direct	June 2000	30,689
Zurich Insurance	July 1986*1	27,945
American Home Direct	Dec. 1960	17,365
Sonpo 24	Mar. 2001	9,820
SAISON AUTO- MOBILE&FIRE	Apr. 1983	8,202
SBI Insurance	Jan. 2008	4,713
E.design Insurance	June 2009	1,100

	FY2012
Sony Assurance	70,712
AXA	35,261
Mitsui Direct	33,830
Zurich Insurance	30,126
American Home Direct	16,594
SBI Insurance	14,288
Sonpo 24	11,810
SAISON AUTO- MOBILE&FIRE	7,990
E.design Insurance	5,140

	(01 1 1111111011)
	9M FY2016
Sony Assurance	66,563
AXA	36,896
Mitsui Direct	27,092
Zurich	26,679
SBI Insurance	23,953
SAISON	22,679
E.design	18,641
Sonpo 24	9,899

^{*} Figures for E.design are net premiums written, those of others are direct net premiums written. (Source: Disclosure from each company)


^{*} Establishment of Japan Branch

^{*} American Home Direct is excluded from the list, since it stopped sales activities for new contracts on Apr. 1, 2016



SBI Life Insurance's Ordinary Income (based on J-GAAP)

SBI Life Insurance suspended sales activities and only managed its assets prior to acquisition, but resumed such activities upon acquisition



The number of contracts: approx. 110 thousand

(annualized premium: JPY 7,799m)

③ Insurance-related business: Small-amount, short-term insurance **Number of Contracts of the Small-amount,** Holdings **Short-term Insurance Companies** 54% increase from Number of Contracts of Earthquake Indemnity the end of Mar. 2012 Acquired in Insurance Resta 20,000 Mar. 2012 14,985 13,318 12,586 15,000 11,909 SBI リスタ少額短期保険 10,798 9,712 [SBI Resta SSI] 10,000 5,000 0 Mar. 2012 Mar. 2013 Mar. 2014 Mar. 2015 Mar. 2016 Mar. 2017 (EOM) **Number of Contracts** 81% increase from the end of Mar. 2013 Acquired in 57.070 60,000 Mar. 2013 46,546 SBI'いきいき少額短期保険 38,753 45,000 31,620 32,444 [SBI IKIIKI SSI] 30,000 15,000 0 Mar. 2013 Mar. 2014 Mar. 2015 Mar. 2016 Mar. 2017 (EOM) **Number of Contracts** 7% increase from the end of Mar. 2016 Acquired in 600.000 1,日本少額短期保険株式会社 Sept. 2016 509,317 [Nihon SSI] 477,988 500,000 450,110 423,430 395,044 400,000

Mar. 2014

Mar. 2015

Mar. 2016

Mar. 2017 49

300.000

Mar. 2013

(EOM)



(2) Asset Management Business

- The Asset Management Business' FY2016 profit before income tax expense (IFRS basis) was JPY 13.9bn
- In FY2016, among the investee companies, 10 companies were IPO'd and 4 companies were M&A'd
- The Group's portion of overseas assets under management expanded to 65%
- Accelerating investments in growth sectors, centering on the FinTech Fund
- Since becoming a subsidiary of the Group, SBI SAVINGS BANK of South Korea's business performance improved significantly, to now support the financial results of the Asset Management Business
- Morningstar Japan achieved a net sales increase for five consecutive fiscal years, and recorded an increase in operating income, ordinary income and net income for eight consecutive fiscal years

Asset Management Business' Financial Results Breakdown



(IFRS, JPY billion)

	FY2012	FY2013	FY2014	FY2015	FY2016
Revenue	33.0	72.7	65.8	91.5	80.4
Profit before income tax expense	6.3	9.0	8.1	17.6	13.9
Profit/loss from the change in fair value and profit/loss on sales of investment securities	9.1	9.4	-4.3	16.1	6.8



FY2016 IPOs and M&As of the SBI Group Investee Companies

	Full-year FY2012	Full-year FY2013	Full-year FY2014	Full-year FY2015	Full-year FY2016	Full-year FY2017 prospects	
IPO·M&A deals	12	12	14	16	14	20	


In FY2016, 10 companies were IPO'd and 4 companies were M&A'd

EXIT Date	Company	Market (Country)	EXIT Date	Company	Market (Country)
July 25	SKCS	KONEX (South Korea)	Nov. 29	Sinqi	China GEM (China)
Aug. 1	Kadmon Holding LLC	NYSE (U.S.)	Dec. 16	Sincere	TSE Mothers
Aug. 8	Carver Korea	M&A	Dec. 20	Renet Japan Group	TSE Mothers
Sept. 19	GL Pharm Tech	M&A	Dec. 21	GRACE TECHNOLOGY	TSE Mothers
Sept. 21	Taraashna Services Private Limited	M&A	Jan. 10	CIS	M&A
Sept. 29	YOUCEL	KONEX (South Korea)	Jan. 24	Eubiologics	KOSDAQ (South Korea)
Nov. 11	SUGENTECH	KONEX (South Korea)	Feb. 23	RENOVA	TSE Mothers


The SBI Group's Trend in Assets Under Management



Proactively rearranged PE business portfolio in FY2016, to recover over JPY 14bn in capital through the sale of securities, and invested over JPY 32bn



(Trend in percentage of domestic and overseas assets under management)



* Calculated by the exchange rate as of the end of Mar. 2017

In 2015, Established "FinTech Fund," the Industry's First FinTech Fund, that Aggressively Invests in FinTech-related Companies



FinTech Business Innovation LPS

- Total commitment amount is JPY 30bn
- Fund investor: 28 regional banks including Bank of Yokohama, Ashikaga Bank, THE SAN-IN GODO BANK and Kiyo Bank, as well as Mizuho Bank and SoftBank invested
- Investment destination: Anticipating investing in 100 or more venture companies with superior technology in the FinTech field

Already decided on investments into <u>46 companies</u>

(Total investment amount to be over <u>JPY 15bn</u> through the FinTech Fund and over <u>JPY 11bn</u> by SBI Holdings)

[Planned EXIT schedule of FinTech investee companies] 2017:4; 2018:8; 2019:7; After 2020:19; TBD:8

<Estimated valuation of FinTech-related investee companies of the SBI Group, which were mentioned in the article "Finding Unicorn companies in Japan" by The Nihon Keizai Shimbun>

Company name Business		Establishment	Valuation
freee	Development of accounting software	2012	JPY 31.5bn
Money Forward	Provision of Personal Financial Management (PFM)	2012	JPY 23.0bn
bitFlyer	Operation of a bitcoin trading website	2014	JPY 20.0bn

Investments Made in the Field of New Technological Innovations through the FinTech Fund





Blockchain

QUOINE Pte. Ltd. (Japan)

ripple

Ripple Labs Inc. (U.S.)



bitFlver. Inc. (Japan)

coinplug (

Coinplug, Inc (Korea)

Robo-advisor

WEALTHNAVI

WealthNavi Inc. (Japan)

お金のデザイン

MONEY DESIGN Co., Ltd. (Japan)

BeaconBank

unerry, inc. (Japan)

Inc. (Japan)

(Israel)

IoT/Security



Cacco inc.

Global Mobility Service, Cacco Inc. (Japan)

RGL

Argus CyberSecurity Ltd.



Remittance/Exchange







Kyash Inc. (Japan)



Episode Six Ltd. (U.S.)

Crowd-funding

Ms music securities Music Securities, Inc. (Japan)



Crowd Realty, Inc. (Japan)

Big data



Treasure Data, Inc.(U.S.)



GiXo Ltd. (Japan)

KOKOPELLI incubate inc.

ΑI

(Japan)

Generic Solution

Generic Solution Corp. (Japan)

COO= N | T ONA

COGENTLABS

Cogent Labs (Japan)

Payment



infcurion, Inc (Japan)

BASE, Inc. (Japan)



Omise Co., Ltd.

(Thailand)

ballon

LIQUID

Liquid. Inc.(Japan)

Exchange Corporation Holdings Ltd. (Japan)



Coinev

Coiney Inc. (Japan) Origami Inc . (Japan)

Banking API



solarisBank AG (Germany)



Moneytree K.K. (Japan)

Loan/Factoring



Social Finance Inc.(U.S.)



FUNDBOX FUND BOX Ltd (U.S.)

Other FinTech



Planet Table Inc. (Japan)

Goodatch

Goodpatch Inc.(Japan)



NestEgg, Inc. (Japan)

Ominkabu

Minkabu, Inc. (Japan)

Accounting/PFM



Money Forward, Inc. (Japan)



freee K.K. (Japan)

SBI SAVINGS BANK:

SBI SAVINGS BANK's Net Income Trend (Based on K-GAAP) Holdings

-Business performance improved dramatically after consolidation in Mar. 2013-

(KRW billion)

	Fiscal year ended June 30 2013	Fiscal year ended June 30 2014	Fiscal year ended June 30 2015	Fiscal year ended Dec. 31, 2015 (irregular financial results for six months)	Fiscal year ended Dec. 31 2016
SBI	-529.2	-329.2	20.2	17.2	74.0
ОК	-5.7 ^{*1}	-8.1	-16.0	5.9	9.2
НК	9.0	21.3	57.3	30.1	10.5
JT Chinae	-27.6	-27.0	1.4	7.1	25.2
Welcome	-2.4 ^{*2}	-12.6	15.7	19.5	35.2
Hyundai	-59.2	-9.5	35.3	56.5	37.5

- > FY 2016 profit before income tax expense attributable to SBI Holdings based on IFRS was JPY 5.6bn
- > 1Q FY2017 net income based on K-GAAP was KRW 20.4bn

^{*1} Irregular financial results for four months, owing to establishment on Feb.15 2013


^{*2} Irregular financial results for two months, owing to establishment on Apr.12 2013

SBI SAVINGS BANK:

(KRW billion)


SBI SAVINGS BANK's Balance of Holdings the Retail Performing Loans Increased Significantly

Balance of Performing Loans*



SBI SAVINGS BANK:

Overall Delinquency Ratio Decreased Dramatically Holdings




Morningstar Japan FY2016 Consolidated Results SBI




[J-GAAP] (Unit: JPY million)

		2015 – Mar. 2016)		FY2016 (Apr. 2016 – Mar. 2017)		
	Amount	Income margin (%)	Amount	Income margin (%)	change	
Net Sales	4,669	-	4,790	_	+2.6	5th consecutive year
Operating Income	1,406	30.1	1,560	32.6	+11.0	8th consecutive year
Ordinary Income	1,406	30.1	1,618	33.8	+15.0	8th consecutive year
Net Income	918	19.7	1,025	21.4	+11.7	8th consecutive year





Morningstar Japan's Information Tool Receives Industry's No.1 Ranking



Source: The Institute of Financial Literacy "Survey on investment trustees' utilization situation of smartphone and tablet"
•Research period: Mar. 2 - Mar. 24 in 2017 •Research target: Sales companies of investment trusts (banks, post offices, credit unions, and securities companies) •Number of valid respondents: 493



(3) Biotechnology-related Business



FY2016 Profit before Income Tax Expense of the Biotechnology-related Business (IFRS)

	FY2015	FY2016	(JPY million)
Total of the Biotechnology-related Business	-6,572	-9,574	
SBI Biotech	-297	**** 737<	Profitable for the first time
Quark Pharmaceuticals ("Quark")	-2,572	-8,270	since its founding
5-ALA-related business	-3,471	-298	
SBI Pharmaceuticals	-1,425	1 91	Profitable for the first time
SBI ALApromo	-587	-233	since its
photonamic *Consolidated in Jan. 2016	38	-41	founding
SBI ALA Hong Kong	-65	-69	
Suzhou Yian Biotech	-1,432	-46	
Others/consolidation adjustments (including foreign exchange/equity method investment loss, etc.)	-72	-1,744	

- ➤ Quark recorded a year-on-year increase in FY2016 loss before income tax expense, owing to <u>significantly higher</u> expenses for the steady progress of several clinical trials, including two Phase III trials since Mar. 2016
- ➤ SBI ALApromo <u>expanded sales by approx. 2.3 times year-on-year</u>, owing to <u>an increase in the number of stores</u> that offer a food with function claims, "ALAplus Tou (Sugar) Down," and regular customers for direct sales, and <u>an increase in OEM sales</u> (e.g., 2 products jointly developed with RIZAP GROUP)
- > photonamic will record milestone payments and other licensing payments in FY2017, that were scheduled to be paid from partner companies in FY2016

FY2016 Financial Results:



5 Years Transition of Biotechnology-related Business ① (SBI Biotech, established in 2007)

Profit before income tax expense (IFRS):

May 2016

Received a partial milestone payment in accordance with development progress of CDC7 / ASK kinase inhibitor program


Sept. 2016

Received a milestone payment by initiating Phase I of out-licensed Anti-ILT7 antibody (MEDI 7734)

Dec. 2016

Out-licensing (3rd case)


Received an upfront payment from the agreement of exclusive marketing rights with Kyowa Hakko Kirin (SBI-9674)



FY2016 Financial Results:




5 Years Transition of Biotechnology-related Business ② (SBI Pharmaceuticals, established in 2008)



FY2016 Financial Results:







R&D Expenses and Investments of the Biotechnology-related Business

➤ R&D expenses of Quark will peak in FY2017 and is expected to decrease afterward

[Expected R&D expenses after FY2017]

FY ending Dec. 2017	FY ending Dec. 2018	FY ending Dec. 2019
approx. USD 72m	💙 approx. USD 62m 💳	approx. USD 37m

Quark is preparing for an independent listing

- For the entire Biotechnology-related Business, will distinguish between "must have" and "nice to have" pipeline developments, according to medical needs and progress in R&D, to actualize a thorough cost reduction
- Moving forward, the SBI Group will avoid making new investments into new fields as much as possible, and instead focus on the existing high growth potential businesses, such as in SBI Biotech and the 5-ALArelated business

SBI Pharmaceuticals Provided Chugai the Exclusive

Marketing Rights of "ALAGLIO® Granule 1.5g ("ALAGLIO"),"

a Diagnostic Agent for Cancer (Carcinoma Vesicae) Treatment

-Received an Upfront Payment in 4Q FY2016-

Granting Chugai the exclusive marketing rights of "ALAGLIO® Granule 1.5g ("ALAGLIO")" in Japan for visualizing tumor tissues during resection of bladder cancer. The approval for manufacture and marketing of ALAGLIO is under application.



Chugai Pharmaceutical

Going forward, SBI Pharmaceuticals will receive royalties from product sales by Chugai

By orally administering ALAGLIO to a patient three hours before surgery and shedding a blue excitation light on the lesion during the surgery, the cancerous portion emits red fluorescence, thereby making it easier to distinguish between cancer and normal tissues

FY2016 Financial Results (SBI Pharmaceuticals):



Presented at the 105th Annual Meeting of the Japanese Urological Association on Diagnostic Agent for Cancer (Carcinoma Vesicae) Treatment

This Agent is the world-first orally administered formulation for photodynamic diagnosis (PDD) for the purpose of visualizing tumor tissue at the operation of the transurethral resection of bladder tumor (TURBT), a resection method of bladder cancer therapy. (Applying for production approval)

Presentation content: The resection* of bladder cancer by using this Agent showed higher sensitivity than the conventional method by using white light only in the patients of non-muscle invasive bladder cancer, which accounts for 70-80% of all types of bladder cancer, in its Phase III clinical trial

*The method to visualize cancer cells by red fluorescence excited by emission of blue light after administration of this Agent

- The primary evaluation point of sensitivity: 54.1% by the conventional method by using white light
 ⇔ 79.6% by the method to visualize cancer cells by fluorescence by using this Agent
- Number of specimens of tumor positive that could be detected: This Agent could detect 46 specimens (25.4%) which could not be detected by the conventional method

The Phase III clinical trial using this Agent was conducted at the respective medical institutions of Kochi University, Nara Medical University, Hamamatsu University School of Medicine, Yamaguchi University and Saitama Medical University International Medical Center

Showed significantly high sensitivity

FY2016 Financial Results (SBI Pharmaceuticals):

Following the Receipt of the Minister of Economy, Trade and Holdings Industry Award, at the 10th Japan Bioventure Awards, SBI Pharmaceuticals Received the "Invention Award" of the Seiichi Tejima Memorial Research Prize, with Professors of the Tokyo Institute of Technology



Memorial Research Prize of Seiichi Tejima* "Invention Award"


*It was established to encourage research at the science and engineering university, and is awarded to stakeholders of Tokyo Institute of Technology. In addition to the Invention Award, there is the Research Dissertation Award, the Doctoral Dissertation Award, the International Student Research Award, the Young Researcher Award, and the Writing Award.

<u>Award-winning theme: Discovery of Photodynamic Therapy or Diagnostic Agents by Means of Infrared Region Radiation</u>

Award received jointly with Tokyo Institute of Technology School of Life Science and Technology Professor Hideya Yuasa and Associate Professor Shun-ichiro Ogura for photodynamic therapy (PDT) by means of infrared-region radiation using 5-ALA and lanthanide nanoparticles

A technology that converts near-infrared radiation (one type of infrared region radiation that penetrates deep into biological tissue) into higher-energy wavelengths for utilization in cancer therapy through the combined use of lanthanide nanoparticles and 5-ALA. It is expected to be used in treatment of deep-seated cancers, which has been difficult until now.

Number of Domestic Stores that Offer Health Foods Containing 5-ALA are Increasing Steadily, and Now Exceed 12,000



The leading drug store chains started selling 5-ALA products:

e.g.


- Tsuruha Holdings approx.1,310 stores
- Welcia approx. 1,300 stores
- cocokara fine 973 stores
- FUJIYAKUHIN approx. 890 stores
- Sundrug approx. 820 stores
- COSMOS Pharmaceutical 802 stores
- SUGIYAKUHIN 138 stores
- Matsumoto Kiyoshi 56 stores
 - → Will start to sell 5-ALA products at over 200 stores

Expanding sales by offering sales promotion measures and POPs that meet the needs of each drug store, as the

occupancy rate of the stores increase



Sales of Foods with Function Claims "ALAplus Tou (Sugar) Down" Increasing Steadily



Recent prizes received by "ALAplus Tou (Sugar) Down":

The 29th Hit Products and Spotlight Products Awards
Won the "Excellence Award for the Hit Item Awards (in the category of health foods/supplements)"

(announced in Jan. 2017)

The 1st Foods with Function Claims / Market Contribution Grand Prize Received "Award for the shining naming and promotion" (announced in Dec. 2016)

Among the 845 foods with function claims received by the Consumer Affairs Agency, "ALAplus Tou (Sugar) Down" (30 capsules) was ranked 13th in sales, in Feb. 2017 (Published in the Apr. 2017 issue of the monthly magazine "H&B Retail")* In the category of blood glucose levels, the product was ranked first for 9 consecutive months (Apr. 2016 - Feb. 2017)



[Summary of the past five years (1)]

Financial Services Business

 With the completion of the establishment of the Internet-based financial ecosystem and thorough pursue of "Customer-centric Principle," all subsidiaries and business divisions achieved profitability, with the exception of subsidiaries that have been established within the past two years. Also, owing to synergies and mutual evolution exerted among the ecosystem component companies, FY2016 revenue achieved an historical high, growing to a business segment capable of high profit levels in spite of adverse market conditions

Asset Management Business

- Owing to Morningstar Japan's sustainable profit growth and SBI SAVINGS BANK's rapid business turnaround, a constant profit source that underpins this business segment has been established
- Through the continued establishment of new funds, both domestically and abroad, such as the FinTech Fund, established a structure that will bear future fruit
- Realize the transition from Japan's SBI to the World's SBI through investments, where the overseas assets under management has become significantly greater than that of the domestic market



[Summary of the past five years (2)]

Biotechnology-related Business

- SBI Biotech and SBI Pharmaceuticals successfully achieved profitability on a non-consolidated basis, owing to the out-licensing of their drug pipeline
- Quark, a subsidiary of SBI Biotech, has two products at the Phase III stage in its drug discovery pipeline, along with a significantly increased cost for clinical trials, but those costs will peak in FY2017, subside in FY2018 and shrink significantly in FY2019
- SBI ALA Hong Kong (consolidated basis) is the intermediate holding company of the 5-ALA-related business, and expects a steady increase in the sales of foods with function claims, along with other health foods and cosmetics, and a steady progress of its drug pipeline clinical trials for peritoneal dissemination of gastric cancer, mitochondrial diseases and cardiac ischemia-reperfusion injury
- → Progressing steadily toward profitability in the Biotechnology-related Business



2. Basic strategy for the next three years based on the summary of the past five years

- (1) In the Financial Services Business, will realize a paradigm shift to the FinTech 1.5-2.0 era, which will cause technological innovations from FinTech 1.0
- (2) The SBI Group will transform itself through the application of FinTech technologies, and by propagating it to the regional financial institutions that is one of the pillars of the regional economy, create a transformation vortex toward a "Regional Revitalization"
- (3) In the Biotechnology-related Business, establishing an independent business structure through the maximization of profits by promoting out-licensing in the pharmaceutical field, and launching new products in the field of health foods, as well as targeting the IPO of major companies
- (4) Promoting the actualization of intrinsic corporate value through measures such as the IPO of Group subsidiary companies to increase market capitalization, and further enhance shareholder returns to increase shareholder value



(1) In the Financial Services Business, will realize a paradigm shift to the FinTech 1.5-2.0 era, which will cause technological innovations from FinTech 1.0



What is FinTech 2.0?

Along with the explosive expansion of the Internet, the SBI Group established its Financial Ecosystem 16 years after its founding

-FinTech 1.0-

- Utilizing elemental technologies such as AI (Artificial Intelligence), big data, IoT, robotics, etc., within the established online financial ecosystem
- Utilizing blockchain with the conventional web-based online financial ecosystem

-FinTech 1.5-

Providing innovative financial services, with blockchain as a core technology

→ Completion of the Blockchain Financial Ecosystem
-FinTech 2.0-


The World of FinTech 2.0 is Entirely Different from Hollings the World of FinTech 1.0 & 1.5

FinTech 1.0 & 1.5

- Web presence is essential
- Exchanging information worldwide through the web
- New solutions for financial services utilizing the web are developed (FinTech 1.5)
- Blockchain can be practically utilized on the web
- Distributed Ledger Technology(DLT) is also developing


FinTech 2.0

- Blockchain is the core technology
- > Enables an exchange of value on the Internet
- Web is not necessarily required





Endeavoring to Complete the Transition Process from the Current FinTech 1.0 to the FinTech 1.5-2.0, within 3 Years





Toward the paradigm shift to the FinTech 1.5-2.0 era, the strategy (Strategy) and means (Technology) necessary for the shift

- ① Expansion of the Group companies' new businesses adopting various elemental technologies, as well as the promotion of demonstration tests utilizing new technologies
- ② Strengthening alliances with FinTech investee venture companies



- 1 Expansion of the Group companies' new businesses adopting various elemental technologies, as well as the promotion of demonstration tests utilizing new technologies
 - (i) Examples of new technology introductions, including AI, big data, IoT and robotics, etc., and the expansion of new businesses
 - (ii) Creation of new financial businesses, and the improvement of operational efficiencies through the utilization of blockchain, a core technology of the FinTech 2.0 era



(i) Examples of new technology introductions, including AI, big data, IoT and robotics, etc., and the expansion of new businesses

E.g. 1: SBI SEURITIES has Enhanced Its Robo-advisor Services in Collaboration with WealthNavi, a FinTech Venture Investee Company





Partnering with WealthNavi, <u>launched "WealthNavi for SBI SECURITIES</u>," a customized robo-advisors service on Jan. 31, 2017



- ➤ Implementation of a direct login from SBI SECURITIES' website to WealthNavi's website through SSO (Single Sign-On)
- ➤ Planning to provide WealthNavi's smartphone app to SBI SECURITIES' customers, as well as to create a cross-linkage (link installation) between both companies' smartphone app

With <u>approximately 12,000 accounts</u> and <u>customer assets of JPY 5.6bn</u>, evidence of a strong growth in business (as of Apr. 26, 2017)

WealthNavi for SBI SECURITIES

In order to further support the asset formation of neophyte investors, SBI SECURITIES is preparing a partnership with MONEY DESIGN Co., Ltd.

E.g. 2:



SBI Liquidity Market and SBI FXTRADE are Partnering with Microsoft Japan to Develop a FX Trading Service Utilizing Al







Microsoft Japan

Joint development of an Al that automatically responds to inquiries from SBI FXTRADE's service users

With Microsoft Japan's Al know-how, will complement and improve the current customer support services through a real-time response to customers' various inquiries, by introducing a chatbot* that is equipped with deep learning functions

* Chatbot: A computer program which conducts automated conversations with the users



Endeavoring to realize a response level similar to that of humans, which will also be available in the evenings and on holidays

E.g. 3:

SBI Sumishin Net Bank, in a Partnership with WealthNavi, Holdings is Preparing for the Provision of Asset Formation Services by Robo-advisors





Launched <u>"WealthNavi for SBI Sumishin Net Bank," a customized robo-advisors service</u> on Feb. 28, 2017

- ◆ Implementation of a direct login from SBI Sumishin Net Bank's website to WealthNavi's website through SSO (Single Sign-On)
- ◆ As the first Japanese bank, provides a prompt identity confirmation that utilizes API

Customer deposit assets reached JPY 800m (as of Apr. 26, 2017)

In preparation for the provision of <u>Japan's first small amount asset</u> management service, which links up with the settlements made by Visa debit with cash cards or e-money

E.g. 4:

Insurance Business Promotes Concrete Initiatives Holding in Order to Develop Personalized Insurance Products

[Life insurance]







FiNC inc.
A technology venture company specializing in mobile health

Started offering a health management app for policyholders of Whole Life Medical Insurance "MO," as an incentive to join the insurance, as well as for disease prevention, with constant health monitoring of individuals

[Auto insurance]





IoT · Automated driving

In collaboration with companies that possess superior technology related to IoT, such as telematics and automated driving, promoting the further development of such technologies

Further promoting to develop personalized insurance products, where premiums are tailored and calculated according to each policy holder's risk and characteristics, by utilizing advanced technology, such as telematics technology and wearable devices

E.g. 5:




SBI SAVINGS BANK Collaborated with the DAYLI Financial Group (formerly Yello Financial Group) to Prevent Bad Debts, and has Utilized a New Screening Model Based on FinTech Technology from Apr. 2017







A digital financial service company composed of many FinTech start-ups in South Korea, with an affiliated subsidiary that provides big data solutions for financial institutions through the utilization of machine learning technology





(ii) Creation of new financial businesses, and the improvement of operational efficiencies through the utilization of blockchain, a core technology of the FinTech 2.0 era

Growing Importance of Blockchain in the Financial Industry



"Blockchain" referred to as Distributed Ledger Technology

Based on a peer-to-peer network constructed on the Internet, blockchain is a system in which data and processing are distributed on multiple nodes (servers), and is said to be a platform that enables safe processing when trading virtual currencies and various other digital assets as well as trade financing, structured bond origination and various transactions involving multiple parties

-Blockchain introduction effects-


Business efficiency improvement: Realization of flexible business flows through smart contracts*

Cost reduction: Reduction of infrastructure costs and multiple administrative costs in business processes incidental to transactions

High reliability: Assurance of data confidentiality, completeness, and availability

Core technology believed to <u>bring about the greatest evolution and innovation</u>

in finance



[Financial services transactions, where blockchain is assumed to be effectively utilized]

✓ Bonds

- ✓ Cross-border trading
- Derivatives
- ✓ Repurchase transaction
- ✓ Commodities
- ✓ Virtual currencies ... etc.

Moreover, streamlining of daily financial operations, including deposits and withdrawals or settlements, as well as payment of insurance claims through smart contacts* will become possible

To Promote Blockchain on a Full-scale Basis to the Securities Business, Advancing Demonstration Tests and In-house Developments




Collaborating with IBM Japan for the verification of the applicability of blockchain to the financial market infrastructure for bond processing operations

[Challenges toward the practical use]

- Short-term: Technology immaturity, discovery of appropriate application for business
- Medium-term: Formulation of standardized specifications and industry-wide review of business operations
- Long-term: Review of regulations, establishment of governance of distributed systems[Anticipated effects]
 - <u>Business automation and efficiency improvement</u> through distributed systems premised on integration of business operations
 - <u>Cost reduction</u> from construction of a business model that eliminates intermediaries that exist in current business
 - Inexpensive systems infrastructure realized through rejection of over-specification and acceptance of a new approach

By developing the abovementioned demonstration tests, considering the possibility of an <u>ecosystem-type finance platform service</u>, in <u>collaboration with other financial institutions</u> as BaaS (Blockchain as a Service)

In Cooperation with Domestic and Overseas Virtual Currency SBI' Exchanges, Including FinTech Fund Investee Companies, Preparing the Provision of Services Utilizing Various Virtual Currencies



Following the enforcement of the Payment Services (Amendment) Act, considering the provision of services utilizing various virtual currencies, including bitcoin and Ripple's XRP, by sequentially advancing the cooperation between virtual currency exchanges domestically and overseas

- [Offering services (planned)]
- Exchange and trading services for various virtual currencies, including bitcoin and XRP, <u>as well as</u>
 regional tokens*
 - Considering the handling, not only of virtual currencies with floating exchange rates, but also of coins with exchange values of JPY 1 or USD 1
- <u>Exchange of SBI Coin</u> (tentative name), which will be developed within the Group, <u>with various virtual</u> currencies, such as cash, SBI Points and gold
- → SBI Coin: Plans to play a role as a bridge currency for various digital assets and inter-business settlements

^{*}Regional token: Substitute currencies, claim receipts and vouchers distributed within the region



The SBI Group Participates on a Full-fledged Basis in a Blockchain Project Led by R3

-Strengthening the cooperation to utilize blockchain-

- ◆ This consortium led by the U.S. R3 currently has the participation of more than 80 of the world's major financial institutions
- ◆ This represents the world's largest working group that is endeavoring towards the optimization of the financial markets, utilizing blockchain
- ◆ The SBI Group participated in Exodus, a project to compare and evaluate distributed ledgers that R3 leads. The project implemented a verification with other financial institutions, toward commercialization of Corda, a distributed ledger technology for financial institutions, which became open-sourcing in Nov. 2016



The SBI Group, along with other major tinancial institutions of the world, will promote Corda as a global. standard in the financial field

Main financial institutions participating in R3's project

UBS, KBC, US Bank, Well Fargo, Mizuho Bank, Scotiabank, BNPP, SBI, Natixis, ING, Deutsche Bank, OP Financial, ITAU, SGX, MAS, MUFG, CTBC, CMB, Nomura, Western Asset Management, Intesa Sanpaolo, RBC*

* As of Apr. 2017

SBI is proactively promoting the validation of the technology for incorporation into the Financial Services Business



② Strengthening alliances with FinTech investee venture companies

(i) Expanding the API Economy in Collaboration with Investee Companies




-Case example of SBI Sumisin Net Bank-

API (Application Programming Interface)

Mechanism to enable the managing of data and software functions from an outside program source



By connecting FinTech venture companies and banks, will <u>create services suitable for</u> individual customers



Started a collaborative service using Japan's first upgraded API*

Considering API connections with about 10 technology development companies in the accounting and asset management field

^{*}A connection method between systems that enables transactions, such as transfers, between a primary account and a specific-purpose account without service providers having access to the user's login ID, password, or personal information

(ii) SBI Sumishin Net Bank Undertook a Full-scale Provision of a Business Loan Service, Based on Accounting Transactions, in Cooperation with Settlement Agencies and Cloud Accounting Service Companies, Both Within and Outside of the Group





* 100% subsidiary of SBI AXES



(Money Forward's MF cloud series)



Since the service is processed completely online, the shortest processing time of one day from application to execution of lending is possible, enabling a quick and prompt response to the financing needs arising from credit card merchants and cloud accounting service users

- ☐ In Dec. 2016, formed a business alliance with Coiney, Inc. that offers a credit card settlement service which uses smartphones and tablet devices, named "Coiney"
- Expanding alliance partnerships by entering into alliances with cloud accounting services such as freee and A-SaaS



(2) The SBI Group will transform itself through the application of FinTech technologies, and by propagating it to the regional financial institutions that is one of the pillars of the regional economy, create a transformation vortex toward a "Regional Revitalization"



SBI Group's Big Picture

National strategy: Promoting regional revitalization initiatives

Reforming the regional financial institutions with SBI developed strategy (Strategy), and the means that SBI provides (Technology)

-Regional revitalization initiatives from the financial sector-

Bringing about social changes with new FinTech technologies

Through a revitalization of the regional economy, will spread the initiatives to the rest of the nation


By Fully Utilizing the SBI Group's FinTech Business Resources, will Contribute to Regional Revitalization, which is a National Strategy

[Concrete Plan]

- ① To support regional revitalization, will introduce venture investee companies from the FinTech Fund to regional financial institutions
- ② In collaboration with IBM Japan, establishing a support system for FinTech services at regional financial institutions
- ③ Endeavoring to bring about a "Remittance Revolution," by establishing a next generation remittance system in Japan, to become a global standard
- ④ Through the newly planned "SBI Regional Bank Value Creation Fund," expect to vitalize regional financial institutions that play a role in regional revitalization
- **(5)** Expanding investment and financing to financial institutions in the Asia region in collaboration with regional financial institutions

Promoting Initiatives to Realize Regional Revitalization, Holdings Which is a National Strategy


Regional revitalization utilizing various solutions provided by the SBI Group



Improving regional financial institutions' corporate value, and vitalizing regional economic activities



Roadmap for Regional Financial Institutions' Corporate Value Enhancement





1 To support regional revitalization, will introduce venture investee companies from the FinTech Fund to regional financial institutions

Introduction case e.g. 1:



Bank of Yokohama's Collaboration with FinTech **Fund's Investee Venture Companies**

freee

"HAMAGIN Super Business Loan Service partnering with freee":

With the data provision from freee, as the first regional bank, launched a loan service that utilizes data of cloud-based accounting software

Bank of Yokohama

Moneytree Moneytree "Issho Tsucho by Moneytree":

Displays Bank of Yokohama and other multiple bank account information in an integrated fashion



KOKOPELLI incubate



Organized a Business-Academia consortium toward the realization of a business loan service, based on accounting transactions

SBI Investment has accepted a seconded employee from the Bank of Yokohama since June 2016

Introduction case e.g. 2:



THE SAN-IN GODO BANK and Orb's Demonstration Test for E-money Using Blockchain

With Orb's technical assistance, THE SAN-IN GODO BANK <u>performed</u> a demonstration test for the usage of E-money (Gogin Coin) using <u>blockchain</u> (Announced on Nov. 10, 2016)

THE SAN-IN GODO BANK





(Venture investee company of the FinTech Fund)

[Outline of the demonstration test]

Payments for the bank employees' spending at cafeterias and kiosks of THE SAN-IN GODO BANK's headquarter were conducted by the Gogin Coin



Considering the possibility of applying blockchain for banking operations, such as for settlements and contract administration


Promoting the Realization of Financial Businesses Contributing to Regional Revitalization, by Providing a Platform for Issuing Regional Tokens with Orb





■ Description of business: Offering the new platform of finance and commerce market, utilizing blockchain

Promotes a project for the issuance and sales support of regional currencies through the utilization of blockchain



* ASP: A service that enables the utilization of software remotely via the Internet

Securing financial institution's premium funds

e.g.

Local government



SBI Energy establishes electric generation plants (SPC) in cooperation with local governments (e.g. Small hydro generation, Solar power generation)

- As a part of the resource, <u>making profits</u>
 <u>from selling electricity through feed-in tariffs</u>
 <u>for renewable energy</u>
- <u>Financial institutions will implement project</u>
 <u>finance</u> for the power generation business,
 funded in part by the generated profits

Structure of Solar Sharing Implemented by SBI Energy Can be Utilized as a Part of the Resource of Regional Tokens -An example of solar sharing in Sosa City, Chiba-

"Solar Sharing (farming type solar power generation)"

Solar sharing is an arrangement for erecting a support framework on farmland and mounting photovoltaic power generation equipment to engage in solar power generation, while continuing to farm. It is attracting attention as a model that contributes to solving the nationwide problem of abandoned fields and helps to promote agriculture, while producing energy for local consumption and vitalizing local economies

Sosa Solar Sharing Limited Liability Company (a power generation operator)

Members: SBI Energy, Johnan Shinkin Bank, regional companies, and etc.

Returning a part of revenue from sales of electric power to the region as a support fund







Farmers



This project's expected annual output is <u>approx. 1,424 MWh (20-year average)</u>, sufficient to serve <u>approx. 288 households*1</u>. It will contribute to CO₂ reduction of approx. <u>718t-CO₂/kWh*2</u>.

^{*1} Estimated taking average annual power consumption of an average household as 4,936 kWh, based on Japan Photovoltaic Energy Association Labeling Guidelines




② In collaboration with IBM Japan, establishing a support system for FinTech services at regional financial institutions

Establishing a Supporting System for the Introduction of Holdings Various FinTech Services to Regional Financial Institutions

Proposing an assortment of FinTech venture companies' services and systems to regional financial institutions

Minimizing regional financial institutions' introductory costs through joint developments






③ Endeavoring to bring about a "Remittance Revolution," by establishing a next generation remittance system in Japan, to become a global standard

Established SBI Ripple Asia on May 18, 2016, with Ripple Labs, Inc., which is Developing a Next Generation Settlement Platform



- Aggressively working on "Beyond Blockchain"-




- A provider of a settlement platform utilizing Ripple's distributed financial technology in Asia including Japan
- The Japan Bank Consortium was established with Japanese financial institutions (Oct. 2016)

Ripple's technology base:

- > It is based on the payment system (ILP: Interledger Protocol) that connects the ledgers under the concept of distributed ledger technology, which can further advance interbank settlements more closely
- Unlike Bitcoin based on blockchain, <u>ILP is even faster</u> (within 1 second) to complete processing

Drastic Reduction of Remittance Cost in International Remittance System Utilizing Ripple's Settlement Platform

Generally, international remittance is <u>20.9 bps</u> against the settlement amount, whereas international remittance utilizing XRP, Ripple's virtual currency, through Ripple's system is <u>8.3 bps</u>, or a <u>60% cost reduction</u>



^{*} Source: Ripple Insight (Feb. 23, 2016)

^{*} Remittance costs include the spread, currency hedging, operation costs and settlement costs

"Remittance Revolution" by Establishing a Next Generation Remittance System in Japan



- ✓ Established the Japan Bank Consortium with domestic financial institutions (secretariat: SBI Group) to centralize domestic and foreign exchange utilizing blockchain-related technology (distributed ledger technology)
- ✓ The Consortium plans to <u>use virtual currencies utilizing blockchain to verify</u>
 the time and convenience required for remittance between banks
- ✓ With this new remittance system, it is also thought that the cost borne by the banks to develop and maintain the interbank payments system will be reduced to about one tenth of the current cost

Centralize domestic and foreign payments

Reducing operation costs

Settlement on a real-time basis, 24 hours a day

Reducing payment infrastructure costs

Reducing banks' payment costs

Reducing customers' commission fees



The Japan Bank Consortium (Established in Oct. 2016)

- Participating financial institutions in "The Japan Bank Consortium" increased to 56 banks (president bank: Resona Bank, secretariat: SBI Ripple Asia, SBI Holdings)
- With new working groups on commercialization and advanced experiments of blockchain and virtual currency from FY2017, it will make continued progress towards commercialization by comprehensively examining multiple aspects including system development, operation, risk and standardization

Participating Financial Institutions (56 banks):

Reginal banks & Second-tier regional banks (41			
Regional banks (34 banks)	The second-tier regional banks (7 banks)	Online banks (5 banks)	Others (10 banks)
Aomori Bank, Ashikaga Bank, The Awa Bank, The Senshu Ikeda Bank, THE IYO BANK, The Bank of Iwate, Oita Bank, The Bank of Okinawa, The Gunma Bank, San-in Godo Bank, THE SHIGA BANK, The Shikoku Bank, 77bank, The Shimizu Bank, The Juroku Bank, Suruga Bank, The Daishi Bank, The Chiba Bank, The Chiba Kogyo Bank, The Chugoku Bank, Tsukuba Bank, THE TOHO BANK, THE NISHI-NIPPON CITY BANK, THE HACHIJUNI BANK, The Hyakugo Bank, Hiroshima Bank, The Fukui Bank, Hokuriku Bank, The Michinoku Bank, The Musashino Bank, The Yamagata Bank, The Yamaguchi Bank, Bank of Yokohama, Bank of The Ryukyus	The Ehime Bank, The Keiyo Bank, The Tokyo Star Bank, The Towa Bank THE TOCHIGI BANK, North Pacific Bank, The Yachiyo Bank	AEON Bank, SBI Sumishin Net Bank, Seven Bank, Sony Bank, Daiwa Next Bank,	ORIX Bank, The Shoko Chukin Bank Shinkin Central Bank, Shinsei Bank, The Norinchukin Bank, Mizuho FG, Sumitomo Mitsui Trust Bank, BTMU, The Nomura Trust and Banking, Resona Bank

The Japan Bank Consortium Successfully Completed a Pilot Implementation of "RC Cloud," a Unified Platform for Both Domestic and Cross-border Payments



Completed a pilot implementation of "RC Cloud," which is a Japan-originated and the first initiative in the world. "RC Cloud" is a cloud-hosted platform on a unified platform by utilizing "Ripple solution"

Confirmed that participating financial institutions were able to execute domestic and cross-border money transactions on RC Cloud, which is powered by Ripple solution, in a pilot environment

<Schedule for commercial use>

Until Mar. 2017

Completion of construction of RC Cloud

Summer-Winter in 2017

Start of commercial use for cross-border payments


By the end of 2017

Initial launch of commercial use for domestic payments

After 2018

Expansion of commercial use for domestic payments

Image of "RC Cloud" pilot implementation:



Ten More Financial Institutions Join Ripple's Global Payments Network*



(Announced on Apr. 26, 2017)

New participating financial institutions:

*A network of financial institutions utilizing Ripple

- 1. MUFG
- 2. BBVA (Banco Bilbao Vizcaya Argentaria)
- 3. SEB (Skandinaviska Enskilda Banken)
- 4. Akbank
- 5. Axis Bank
- 6. YES BANK
- 7. SBI Remit
- 8. Cambridge Global Payments
- 9. Star One Credit Union
- 10. eZforex.com

Currently, over 75 banks are participating

Comment by Bank of Tokyo-Mitsubishi UFJ:

"We are very pleased to be working with Ripple to provide new types of payments services to change our customers' experience using the power of the blockchain technology. To demonstrate our commitment to the technology, we are joining the Japan Bank Consortium to collaborate with other Japanese banks move to commercial use of Ripple's global network. I do believe we can bring our experience from the Japan Bank Consortium to the Global Payments Steering Group."



Bank of Tokyo-Mitsubishi UFJ Announces Participation in Ripple-led Global Banking Consortium (GPSG: Global Payments Steering Group)

- ◆ GPSG: International bank remittance consortium applying Ripple's distributed ledger technology, founded in Sept. 2016. Established to formalize standards for activity using Ripple, so that financial institutions can smoothly introduce Ripple's software and start using it, leading to network dissemination
- ◆ Chairman: Mr. Donald Donahue (Ripple's Advisor)
- Participating financial institutions (7 banks):
- ▶ Bank of America Merrill Lynch(U.S.) ▶ Royal Bank of Canada (Canada)
- > Santander (Spain)
- Standard Chartered (U.K.)
- Westpac Banking Corporation(Australia)

- Canadian Imperial Bank of Commerce(Canada)
- Bank of Tokyo-Mitsubishi UFJ (Japan)

*As of the end of Mar. 2017

Efforts toward commercial use of Ripple's distributed ledger technology are accelerating



4 Through the newly planned "SBI Regional Bank Value Creation Fund," expect to vitalize regional financial institutions that play a role in regional revitalization

The SBI Group Companies are Already Collaborating with Many Domestic and Overseas Financial Institutions, and will Endeavor to Further Strengthen Their Relationships and Partnerships, Moving Forward



Financial institutions that have invested in the FinTech Fund

→ Over 30 companies including, 28 regional banks

SBI証券 [SBI SECURITIES]

Partner financial institutions in the marketinduced business

→ 7 companies, including 4 regional banks

M\(\tag{RNINGSTAR}\)

Financial institutions adopting apps

→ 70 companies including 33 regional banks



[InsWeb]

Service participant company

→ 37 insurance companies



E-LOAN

Partner financial institutions

→ 101 companies, including 45 regional banks



→ 29 major domestic and overseas financial institutions



SBI Business Solutions

Financial institutions deployed with cloud services

→ 20 companies, including 14 regional banks



PTS participating securities company

→ 30 major securities companies



Partner financial institutions

→ 15 regional banks



Strengthening Cooperation with the Regional Financial Institutions through the FinTech Fund and "The Japan Bank Consortium"



Participating Financial Institutions of The Japan Bank Consortium (Reginal banks & Second-tier regional banks: 43 banks)

THE AKITA BANK, The Bank of Iwate, The Awa Bank, Oita Bank, The Bank of Okinawa, The Gunma Bank, THE SHIGA BANK, 77bank, The Juroku Bank, SURUGA bank, The Daishi Bank, The Chiba Bank, The Chiba Kogyo Bank, The Chugoku Bank, The Tokyo Star Bank, The Bank of Nagoya, The Nishi-Nippon City Bank, The Hachijuni Bank, The Fukui Bank, The Musashino Bank, The Yamagata Bank, The Yamaguchi Bank

Aomori Bank, Ashikaga Bank, The Senshu Ikeda Bank, THE IYO BANK, The Ehime Bank, The Keiyo Bank, San-in Godo Bank, The Shikoku Bank, The Shimizu Bank, Tsukuba Bank, THE TOHO BANK, The Towa Bank, THE TOCHIGI BANK, The Hyakugo Bank, Hiroshima Bank, North Pacific Bank, Hokuriku Bank, The Michinoku Bank, The Yachiyo Bank, Bank of Yokohama, Bank of The Ryukyus

The Kita-Nippon Bank, The Kiyo Bank, The Bank of Kochi, The Daisan Bank, The Tokushima Bank, Nagano Bank, The Hokuto Bank

Regional Financial Institutions Investing in the FinTech Fund (28 banks)

Others (16 banks)

ORIX Bank, The Shoko Chukin Bank, Shinkin Central Bank. Shinsei Bank. The Norinchukin Bank, Mizuho Bank, Sumitomo Mitsui Trust Bank. The Bank of Tokyo-Mitsubishi UFJ Mitsubishi UFJ Trust and **Banking Corporation** The Nomura Trust and Banking. Resona Bank, AEON Bank, SBI Sumishin Net Bank, Seven Bank. Sony Bank, Daiwa Next Bank



Toward Further Strengthening the Relationships with Regional Financial Institutions

Planning the establishment of a new fund (target fund size: JPY 100bn) for regional financial institutions, to increase their corporate value

- ✓ Raising capital from financial institutions for a new fund, in order to invest in promising regional financial institutions that are capable of improving corporate governance and increasing corporate value, through the provision of FinTech support by the SBI Group
- ✓ By utilizing the fund to eliminate interbank cross-shareholdings, an effective utilization of capital becomes possible



Settlor company: SBI Asset Management

Sales company: SBI SECURITIES

Through the SBI Group's Support for the Introduction of SBI FinTech, Realizes Increase in Both the Regional Financial Institutions' and the FinTech Investees' Corporate Values


-Will lead to the realization of a higher management fund performance-

FinTech Fund (Fund size: JPY 30bn)

-Established in Dec. 2015

-28 of regional banks have already invested

-Going forward, anticipating investing in 100 or more domestic and overseas companies



- ✓ SBI Group's cooperation with WealthNavi
- ✓ SBI Sumishin Net Bank's expansion of the API economy



SBI Regional Bank Value Creation Fund

(Target fund size: JPY100bn)

Planning the establishment of a fund for regional financial institutions to increase their corporate value by assisting in the introduction of FinTech

FinTech venture investees

Enhance profitability of regional financial institutions by utilizing FinTech

<u>FinTech ventures' revenue will</u> <u>increase as the number of users</u> of their services increase Through an increase in the corporate value of the investee companies, will realize a higher management fund performance

By providing packaged software jointly developed by the SBI Group and FinTech companies, will lead to the creation of a distribution market, as well as a reduction in the introductory costs



⑤ Expanding investment and financing to financial institutions in the Asia region in collaboration with regional financial institutions




Establishing a Global Investment Structure Centered on Asia






The SBI Group has an Extensive Investment Track Record in Overseas Financial Institutions



^{*} SBI's shareholding percentage corresponds to a total percentage based on the IFRS criteria for subsidiary companies and subsidiary funds of the Group

By Utilizing the SBI Group's Expertise in Overseas Investment and Holdings Financing, in Collaboration with Regional Financial Institutions will Invest or Finance in Overseas Financial Institutions, Primarily in Asia, to Expand the Overseas Financial Ecosystem



- ✓ By leveraging the SBI Group's overseas network, will provide regional financial institutions with overseas investment and financing opportunities
- ✓ Through the alliance with regional financial institutions, expanding the Group's businesses on a global basis



(3) In the Biotechnology-related Business, establishing an independent business structure through the maximization of profits by promoting out-licensing in the pharmaceutical field, and launching new products in the field of health foods, as well as targeting the IPO of major companies

SBI Biotech:

SBI Biotech's Drug Discovery Pipeline Progress



SBI Biotech achieved profitability on a single-year non-consolidated basis this fiscal year, for the first time since its founding, through the progress of out-licensing of its existing drug pipeline, as well as other successful out-licensing activities

	Licensing partner(timing)	Adaptation disease	Progress	
MEDI7734 (Anti-ILT7 antibody)	MedImmune, LLC. (Subsidiary of AstraZeneca) (Sept. 2008)	Autoimmune diseases (Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome, Dermatomyositis, etc.)	Phase I	MedImmune is conducting Phase I clinical trial. SBI Biotech recorded an allotted milestone payment in 2Q FY2016 (undisclosed amount)
SBI-9674	Kyowa Hakko Kirin Co., Ltd (Dec. 2016)	Autoimmune diseases	Pre-clinical (Kyowa Hakko Kirin promoting development)	Conducted license agreements at the end of 2016→SBI Biotech received an upfront payment and recorded it in 3Q FY2016 (undisclosed amount) *Further receipt of milestone payments in accordance with development progress is also expected
Cdc7 inhibitor	Carna Biosciences, Inc. (May 2014)	Cancers	Pre-clinical (plan to apply for clinical trial in 2017)	Carna Biosciences entered into an out- licensing agreement with Sierra Oncology →SBI Biotech received a partial milestone payment in June 2016 *Further receipt of milestone payments in accordance with development progress is also expected
GNKS356	Independently	Psoriasis / Systemic Lupus Erythematosus (SLE)	Pre-clinical	Selected as Japan Agency for Medical Research and Development's (AMED) project of promoting support for drug discovery on orphan drugs (from FY2015 to FY2017) →Received subsidies (up to JPY 200m per fiscal year) and promoting R&D
SBI-3150	Independently	Various diseases caused by pDC / activated B cells	Pre-clinical	Using the advantages of the development concept, we are actively engaged in outlicensing activities



Drug Pipelines Including Ethical Pharmaceuticals Utilizing 5-ALA under the SBI Group

Fields Pipeline projects	Pineline	Current status				
		•	Phase I	Phase II	Phase III	Applica- tion
	1	Carcinoma vesicae	in applic	ation for produ	ction approval	
Diagnostic agent (PDD)	2	Peritoneal dissemination of gastric cancer*	Preparation fo			
	3	Cisplatin nephropathy protection	Completed an ii		Preparation corporate to II) is underv	rial (Phase
Drug to treat	4	Mitochondrial diseases*	Preparation for Phase III is Considering an out-licensing			
	5	Cardiac ischemia- reperfusion injury*	Preparation for Phase II is underway	Univer	uled by Oxford sity and Birmi sity Hospital i	ingham
Photodynamic therapy (PDT)	6	Brain tumors* (by photonamic, a wholly owned subsidiary)	Phase II is underway		- J Hoopitul	

Prospects for the next three years
Launch
Completed Phase III / Out- licensing
Completed Phase II
Completed Phase III / Out- licensing
Conducting Phase II
Conducting Phase II

Out-licensing:

- ✓ Therapeutic drugs for diabetes and malaria infection (to Neopharma, UAE pharmaceutical company, in Oct. 2016)
- ✓ "ALAGLIO® Granule 1.5g," diagnostic agent for cancer treatment (carcinoma vesicae), (to Chugai in Mar. 2017)

Already launched:

- Diagnostic agent for cancer treatment (brain tumor) "ALAGLIO" (by SBI Pharmaceuticals)
- ✓ Same as above, "Gliolan" (by photonamic)
- Drug for treating actinic keratosis "Alacare" (by photonamic)

^{*}Investigator-led trial



Progress of Business Projects with Neopharma, UAE's Pharmaceutical Company, and the Prospects for Contributions to SBI Pharmaceuticals

Projects	Current status	Expectations about future profitability	
Therapeutic drugs for diabetes (to Neopharma)	Phase II/III clinical trials will be conducted at other overseas medical institutions →Phase II protocol will be approved soon	Receipt of milestone payments after the start of Phase III	
Therapeutic drugs for malaria infection (to Neopharma)	Started development at the National Institute of Malaria Research in India in cooperation with Neopharma Phase II protocol will be approved soon		
Overseas sales (Joint venture with Neopharma / SBI Group's Shareholding:49% →Profit allocation 50:50)	Established a joint venture, "SBI Neopharma FZ-LLC," in Dubai		
	 Overseas sales of all the 5-ALA related products including the health foods, cosmetics, feeds and fertilizers containing 5-ALA to be developed by SBI Pharmaceuticals and Neopharma Overseas sales of the pharmaceuticals using 5-ALA (therapeutic drugs for diabetes, malaria infection and diagnostic agent for brain tumor treatment (plan)) to be developed by Neopharma 	Plan to first launch health foods in the Middle East and Russia in 2Q FY2017	

5-ALA-related business (SBI Pharmaceuticals):



Expanding the Development Areas to Related Fields, Mainly in Strictly Selected Pipeline

Mechanism that PPIX accumulates in cancer

Utilizing the mechanism that cancer cells can not metabolize 5-ALA to heme and 5-ALA accumulates as protoporphyrin IX (PPIX) in cancer cells

Development at the clinical phase

Diagnostic agent (PDD)

- 1 Brain tumor: Launched
- ② Carcinoma vesicae: In application for production approval
- ③ Peritoneal dissemination of gastric cancer: Preparation for Phase III is underway

Ongoing development themes

Additional treatment of other types of cancer

Development of Photodynamic therapy (PDT)

Cancer screening by urinalysis

Part of the accumulated porphyrin flows into body fluids such as blood and urine, so the presence or absence and size of cancer cells can be estimated by measuring the amount of porphyrin in body fluid

Mechanism by which ALA is a raw material of heme

Application of cell activation and antioxidant effect produced by heme synthesized from 5-ALA incorporated into cells

Development at the clinical phase

Mitochondrial diseases (Preparation for Phase III is underway)

Cisplatin nephropathy protection (Preparation for Phase II is underway)

Cardiac ischemia-reperfusion injury (Preparation for Phase II is underway)

Diabetes (Out-licensing)

Malaria Infection (Out-licensing)

R&D topics under way

Parkinson's disease

Alzheimer disease

Prevention of severe influenza

Diabetic nephropathy

5-ALA-related business:



Established "Keio-SBI 5-ALA Laboratory" with the Health Science Laboratory of Keio Research Institute at SFC, Keio University, to Enhance Basic Research on 5-ALA and Provide Information to the World



Engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-ALA

Keio Research Institute at SFC, Keio Univ.

"Health Science Laboratory"

- Promoting research in the field of "Health," with a view toward societal applications, in order to lead as a developed country with the highest life expectancy
- Representative: Kazuo Tsubota (Professor, Department of Ophthalmology, Graduate School of Medicine, Keio University) and Mitsuhiro Watanabe (Professor, Media and Governance, Keio University Graduate School)

5-ALA is an amino acid created in mitochondria and its productivity is known to decrease with age

Professor Mitsuhiro Watanabe's latest book:
"You can Extend Your Healthy Life Expectancy!
-Infinite possibilities of 5-ALA, the cell activating ingredient of interest"



Established "Keio-SBI 5-ALA Laboratory"

(at Keio University Shonan Fujisawa Campus (SFC))

Promotion of research on improving effects by 5-ALA on diseases associated with aging



Toward Early Profitability of SBI ALApromo

Examples of specific measures in the future:

- Further sales expansion of a hit product "ALA Plus Tou (Sugar) Down" (including an increase in regular customers for direct sales and the number of stores)
- Launch of new products utilizing 5-ALA that appeal to various customers:
 - "Meno. STOP" (Supplement focusing on female-specific hormone balance)
 - "Body Shape" (Increased sugar and fat metabolism with double effect of 5-ALA and carnitine)
- > Launch of foods with functional claims based on R&D for every fiscal year
 - FY2017: A food with functional claims utilizing 5-ALA for recovery from fatigue (Institution conducting clinical trials: Hiroshima Univ.)
 - FY2018: A food with functional claims for male menopause improvement (Juntendo Univ.)
 - FY2019: A food with functional claims for improved motor functions (Juntendo Univ.)
- Expansion of supplements utilizing ingredients other than 5-ALA, and general food products (considering changing the company name)
 - As a first step, launch of a food with functional claims utilizing gingko bilboa
 - Started R&D on germination brown rice from FY2017, toward a launch in FY2018
- > Development of skincare products in the mail-order market
 - Launch of products for cleansing and facial wash in FY2017, adding beauty essence in FY2018, toward an early profitability
- ➤ Development of OEM business (OEM: Original Equipment Manufacturer: Manufacturing another company's product under their own name or branding)
 - Actively developing OEM for health foods and cosmetics
 - Launch of "ALAplus 75" utilizing high level of 5-ALA, only available in clinics

Regarding cosmetics utilizing 5-ALA, scientific studies by Professor Hiroyuki Kobayashi of Juntendo University School of Medicine is under way



- (4) Promoting the actualization of intrinsic corporate value through measures such as the IPO of Group subsidiary companies to increase market capitalization, and further enhance shareholder returns to increase shareholder value
 - **1 SBI FinTech Solutions**
 - ② SBI Insurance Group (Insurance holding company)
 - **③ SBI Capital Management**
 - **4** SBI Biotech
 - **(5) Quark Pharmaceuticals**
 - **© SBI ALA Hong Kong**

Subsidiary Company Listing Strategy Trend



-12 companies listed since the establishment of the Group-

1999-2007

Policy: Promoting listing of subsidiary companies to ensure growth funds

Develop Group subsidiaries into companies capable of launching IPOs as soon as possible. As autonomous, independent companies, subsidiaries that complete IPOs fully utilize their own financing capabilities to undertake self-propagation without placing financial demands on the parent company

2007-2015

Securities exchanges signal a suppressive stance toward parent-subsidiary listings in "TSE stance on the listing of companies that have parent companies," announced by the Tokyo Stock Exchange in June 2007, and "Securities exchanges' stance related to the listing of core subsidiaries," announced jointly by stock exchanges in Oct. 2007

Changed the policy and decided basically not to list subsidiary companies conducting core businesses, in order to promote financial conglomerate management

SBI SECURITIES, which is the largest "cash cow" of the Group, became a wholly owned subsidiary (Aug. 2008)

2015- Parent-subsidiary listing of Japan Post Group (Nov. 2015)

Started to reconsider the IPOs of subsidiary companies

Actualizing the Intrinsic Corporate Value in Light of the Initial Public Strategies of the Group Subsidiaries



[Basic policy on IPO strategies of subsidiary companies]

- If it is preferable to actualize the intrinsic corporate value by listing the company toward the visualization of major businesses' value
- If it is necessary for the company to improve its IT infrastructure and other largescale capital investments on an ongoing basis, or to increase its capital due to a business that requires a large amount of working capital
- In the development of domestic banking and insurance businesses through subsidiaries, if a flexible establishment of an operational system is necessary to preserve managerial freedom under the Japanese legal system
- If the company is <u>required to maintain a neutral position</u> in the business that it conducts
 → (e.g.) Morningstar Japan: Listed on NASDAQ Japan (currently TSE JASDAQ) in June 2000
- When the company creates little synergies between itself and other Group companies, and from the <u>perspective</u> of the Group's overall business portfolio, if it would be beneficial for the company to publicly offer its shares so that its shareholder value could be actualized, or if the <u>company's significance</u> in the overall Group strategy <u>has</u> deteriorated

[List of subsidiaries that are considering listing]

Company name	Business overview
SBI FinTech Solutions	Aggregate FinTech related companies within the Group
SBI Insurance Group	Govern the insurance businesses within the Group
SBI Capital Management	Intermediate holding company of the Asset Management Business
SBI Biotech	R&D etc. of pharmaceuticals
Quark Pharmaceuticals (Quark)	R&D etc. of pharmaceuticals
SBI ALA Hong Kong	Intermediate holding company of the Biotechnology-related Business


① SBI FinTech Solutions:



Reorganizing SBI AXES as SBI FinTech Solutions (tentative), by Aggregating Three FinTech-related Companies of the SBI Group

Given that the preexisting SBI AXES' EC payment business has high affinity with FinTech, the company will expand its business as the newly formed SBI FinTech Solutions

* SBI AXES plans to change corporate name to SBI FinTech Solutions from July 7, 2017



① SBI FinTech Solutions:

Initiatives of Three Acquired FinTech-related Companies SB





- Provide international remittance service that can complete remittances in 10 minutes at shortest
- Prepare utilization of international remittance service based on blockchain, with settlement in virtual currencies



- Provide a service that ties borrowers and investors via the Internet
- Focus on building a P2P platform



- Provide cloud service for accounting and settlement of expenses, and account aggregation software that corresponds to over 1,530 financial institutions
- Strive to provide highly valued services utilizing FinTech, through API connection etc.


SBI AXES will endeavor to further enhance corporate value by accelerating its growth by placing these at the core of its operation, as well as by developing services with high customer benefits through the aggressive adoption of new elemental technologies

② SBI Insurance Group (insurance holding company):

SBI Insurance Group Started Its Operations on March Holdings 31, 2017, and is Considering an IPO as an Insurance Holding Company

SBI Insurance Holding Company Planning Co., Ltd., which was established as a preparatory insurance holding company, obtained approval from the relevant regulators, and was subsequently reorganized on Mar. 31, 2017 with a company name change to SBI Insurance Group Co., Ltd., to start its operations

[Organizational chart of the SBI Group's insurance business]



As an insurance group led by the SBI Insurance Group, will endeavor to become a new era insurance group, by working on measures such as allying with companies outside of the Group and utilizing FinTech, as well as by promoting efficient management

③ SBI Capital Management:

As Soon as Preparations are Completed, SBI Capital Management's IPO will be Considered, an Intermediate Holding Company of the Asset Management Business



Business overview: Specializing in the Group's asset management business, with an efficient and central management of funds and foreign exchange for the said business

Primary subsidiary companies (plan):



Operate and manage venture capital funds

GP of overseas funds

Operate and manage overseas venture capital funds

Overseas financial institutions

SBI SAVINGS BANK etc.



SBI Biotech's Listing Considerations

-Achieved profitability on a single-year non-consolidated basis in this fiscal year for the first time since its founding-

- > SBI Biotech has proprietary platforms concerning plasmacytoid DC (pDC), considered as the "control tower" of the immune system, as its drug discovery target, and the future development of revolutionary cancer and autoimmune disease therapies through immune control may be expected
- Already succeeded in <u>out-licensing three pipeline products to pharmaceutical</u> <u>companies at an early stage</u>
 - ① MEDI7734 (Anti-ILT7 antibody): Out-licensing to MedImmune, LLC., a subsidiary of AstraZeneca
 - ② SBI-9674: Out-licensing to Kyowa Hakko Kirin Co., Ltd
 - 3 Cdc7 inhibitor : Out-licensing to Carna Biosciences, Inc.
- Out-licensed pipeline assets are expected to sequentially advance to the clinical trial stage, and if drug discovery pipeline monetization steadily progresses, establishment of a value chain will be within range



In order to realize SBI Biotech's sole IPO, separating its wholly owned subsidiary Quark, and selecting a lead managing underwriter to initiate listing discussions

⑤ Quark:



Quark has two products at the Phase III stage in its drug discovery pipeline


- QPI-1002: Kidney transplantation (DGF) (Licensing partner: Novartis International AG)→Phase III scheduled to end by Dec. 2019 (Total milestone payments: USD 670m, *approx. JPY 70bn)
- QPI-1007: Non-arteritic anterior ischemic optic neuropathy (NAION) (Licensing partner: Biocon Ltd of India)→Phase III scheduled to end by July 2019 (Earning royalties after marketing)

Considering the spin-off of Quark from SBI Biotech for an independent listing

Since Quark has two products at the Phase III stage in its drug discovery pipeline, it has satisfied the conditions for a public offering on the NASDAQ market. Continuing discussions with several securities firms in preparation for an IPO on the U.S. NASDAQ market, including preparations such as IPO application documentation

(6) SBI ALA Hong Kong:

SBI ALA Hong Kong, an Intermediate Holding Company involved Holdings in the 5-ALA-related Business, will be Considered for an IPO





[Appendix]



(1) The Company's current stock price, and the method in calculating the estimated corporate value



SBI Holding's Recent Stock Price

Market cap (based on the closing price of Apr. 27, 2017): JPY 350.8bn




Source: Bloomberg



Change in PBR of SBI Holdings

PBR = Closing price at the end of FY / Net assets per share at the end of FY



^{*1} PBR of SBI Holdings for Apr. 27, 2017 is calculated based on the BPS of the end of Mar. 2017.

Note: PBR of SBI Holdings prior to FY2011 is calculated based on J-GAAP BPS.

Source: TSE website

^{*2} EPS of FY2016 (JPY 159.38) is used to calculate SBI Holdings' PER.

Corporate Value by Business Segment Valuation Each Business Segment Valuation is Conservatively Estimated

■ Sum of the values by segment (as of Apr. 27, 2017)

(JPY billion)

	Valuation of each segment (theoretical value)
Financial Services	603.9
Asset Management	221.4
Biotechnology-related	88.4
Subtotal	913.7 (+) –
External Debt (SBIH's non-consolidated-base borrowing recorded on the consolidated B/S as of Mar. 2017)	-249.5
Sum Total	664.2 (+)*

- Business valuation per share: JPY 4,069 ←

- Business valuation per share after deduction of external debt: <code>JPY 2,958</code>

Out of the major Group companies, 11 are profitable companies that are not included in the above calculations (Total FY2016 Profit before Income Tax Expense: approx. JPY 4.4bn)

^{*} Since the figure is a simple sum of the values of each segment with interest-bearing liabilities of SBIH not taken into account in the calculation, the abovementioned business valuation per share does not show the theoretical stock price of SBIH.



Valuation by Segment Estimated by SBI (1) Financial Services Business ① SBI SECURITIES -(i)

(1) SBI SECURITIES

Valuation is conservatively estimated at JPY 463.5bn

(based on the closing prices of Apr. 27, 2017)

Estimation of the valuation is as follows:

Calculated according to the Comparable Public Company Analysis

Compares the market cap and profits of a comparable public company, Matsui Securities.

Valuation of SBI SECURITIES is calculated as the mean of the two values [(A) and (B)] resulting from the equations below

```
Matsui's PER (*1) × SBI SECURITIES's Net Income (FY2016) ... (A)
```

Matsui's PBR (*2) × SBI SECURITIES's Net Asset (*3) (as of Mar. 31, 2017) ... (B)

^{*1} PER of Matsui is calculated by its net income per share for FY2016.

^{*2} PBR of Matsui is calculated by its BPS as of Mar. 31, 2017.

^{*3} Represents SBI SECURITIES' balance of net asset excluding short-term loans receivable from SBIH




Valuation by Segment Estimated by SBI (1) Financial Services Business ① SBI SECURITIES -(ii)

Is SBI SECURITIES' valuation reasonable?

Comparison of SBI SECURITIES Matsui Securities *Calculated by the closing prices of Apr. 27, 2017

(9M FY2016)	SBI	SECURITIES	Matsui Securities
Valuation (market cap) *		JPY 463.5bn	JPY 231.8bn
Deposit assets (Dec. 2016)	No.1	JPY 10.8tn	JPY 2.3tn
Number of accounts (As of the end of Dec. 2016)	No.1	3.84 million	1.09 million
Share of individual stock brokerage trading value	No.1	34.7%	13.0%
Operating income	No.1	JPY 38.0bn (down 4.8% YoY)	JPY 14.9bn (down 31.3% YoY)



Valuation by Segment Estimated by SBI (1) Financial Services Business ② SBI Sumishin Net Bank

② SBI Sumishin Net Bank

Estimates the valuation of SBI Sumishin Net Bank with high growth potential in terms of profitability and scale at

<u>JPY 115.5bn</u> → <u>JPY 57.8bn</u> (based on the closing prices of Apr. 27, 2017) (Shareholding of the SBI Group: 50.0%)

Estimation of the valuation is as follows:


Calculated according to the Comparable Public Company Analysis

Compares the profits of comparable public companies of which the deposit balance exceeds JPY 3tn as of the end of Mar. 2016

Median value of estimated PERs of listed local banks SE of which the deposit balance exceeds JPY 3tn (*)

SBI Sumishin Net Bank's Net Income (FY2016)

[Reference] Valuation distribution based on the abovementioned pro forma calculation



Holdings

^{*} Compiled by the Company from the materials disclosed by the listed local banks of which the deposit balance exceeds JPY 3tn as of the end of Mar. 2016



Valuation by Segment Estimated by SBI (1) Financial Services Business ③ SBI Liquidity Market

③ SBI Liquidity Market (including SBI FXTRADE)

Valuation is estimated at JPY 49.8bn (based on the closing price of Apr. 27, 2017)

Estimation of the valuation is as follows:

Calculated according to the Comparable Public Company Analysis

Compares the market cap and profits of comparable public companies, namely Money Partners, and Hirose FX

4 SBI Japannext

Conservatively estimates the valuation of SBI Japannext at

USD 150m → JPY 8.1bn (based on the exchange rate as of Apr. 27, 2017) (Shareholding of the SBI Group: 48.8%)

^{*} PER of Money Partners and Hirose FX are calculated by its net income per share for FY2015.

Valuation by Segment Estimated by SBI (1) Financial Services Business



- **⑤ SBIH Comparison Website Business / ⑥ Other Financial Services Business**
 - **⑤ SBIH Comparison Website Business**

Valuation is estimated at <u>JPY 16.2bn</u> (based on the closing price of Apr. 27, 2017) Estimation of the valuation is as follows:

Calculated according to the Comparable Public Company Analysis

Compares the profits of comparable public companies, namely Kakaku.com

{(Kakaku.com's PER + NEWTON FINANCIAL CONSULTING' PER)}(*)

2

 Provisional amount of net Income of SBIH Comparison Website Business (FY2016)

® Other listed subsidiary and an equity method company in this business segment

	SBI's shareholding pct. (%)	Classification	Listed market	Market cap (JPY billion)	SBI's equity interest of market cap (JPY billion)
SBI AXES	73.8	Consolidated subsidiary	KOSDAQ of KRX	9.1*	6.7
SOLXYZ	23.4	Equity method associate	TSE 1st	7.7	1.8
Sum of the market cap of a listed subsidiary and an equity method associate			16.8	<u>8.5</u>	

(Based on the closing price of Apr. 27, 2017. *Calculated by the exchange rate as of Apr. 27, 2017.)

^{*} PER of Kakaku.com and NEWTON FINANCIAL CONSULTING are calculated by their estimated net income per share for FY2016.

^{*} SBI's shareholding percentage corresponds to a figure based on the IFRS criteria that excludes a percentage of outside shareholder's interest of subsidiary companies and subsidiary funds of the Group.

Valuation by Segment Estimated by SBIH



(1) Financial Services Business: Total Valuation of the Businesses

(1) SBI SECURITIES

(based on the closing prices of Apr. 27, 2017)

Upon comparison with similar listed companies calculated conservatively as JPY 463.5bn

② SBI Sumishin Net Bank

(based on the closing prices of Apr. 27, 2017)

Estimated the valuation of SBI Sumishin Net Bank that has high growth potential in terms of profitability and scale at JPY 115.5bn

JPY 57.8bn (Shareholding of the SBI Group: 50.0%)

③ SBI Liquidity Market (cons.)

(based on the closing prices of Apr. 27, 2017)

Upon comparison with similar listed companies calculated as JPY 49.8bn

4 SBI Japannext

(based on the exchange rate of Apr. 27, 2017)

Upon the conservative estimated valuation of USD 150m → JPY 8.1bn

(Shareholding of the SBI Group: 48.8%)

⑤ SBI Comparison Website Business

(based on the closing prices of Apr. 27, 2017)

Upon comparison with similar listed companies calculated as JPY 16.2bn

(6) Total market cap upon SBIH's shareholding of a listed subsidiary and an equity method company in this segment

The market cap of SBI AXES and SOLXYZ (Shareholding of the SBI Group) <u>JPY 8.5bn</u> (based on the closing prices of Apr. 27, 2017)

Total of the valuation above: JPY 603.9bn (The sum according to the SBI Group's shareholding)

Valuation by Segment Estimated by SBIH



(1) Financial Services Business

7 Other Financial Services Businesses (Profitable Entities)

There are many other profitable business entities in this segment

	Business lineup	Profit before income tax expense for FY2016 (JPY billion)	SBI's shareholding pct. (%)
SBI MONEY PLAZA	Insurance agency, financial instruments intermediary service provider, housing loan agency	2.0	100.0
SBI Life Insurance *1	Life insurance	1.6	100.0
SBI Remit	International money remittance service	0.3	100.0

Based on the "Selection and Concentration" policy for the Financial Services Business, regardless of profit contributions, <u>a sale</u>, <u>an IPO or reorganizations</u> <u>within the Group of non-core businesses will be accelerated</u>, though a judgment of the existence or strength of synergies with one of the three core businesses



Proceeds generated may be appropriated to strengthen the three core businesses

^{*1} Considering the particularity of life insurance business, presents the recurring income based on J-GAAP, not that of based on IFRS.

^{*2} SBI's shareholding percentage corresponds to a total percentage based on the IFRS criteria for subsidiary companies and subsidiary funds of the Group. 452



Valuation by Segment Estimated by SBIH (2) Asset Management Business -1

Asset Management Business

Valuation for this segment is conservatively estimated at approx. JPY 221.4bn Reference>

JAFCO's Market Cap: JPY 196.1bn (based on the closing price of Apr. 27, 2017)

Valuation estimation is the sum of the valuation (i)-(iv) below.

(i) Value of holding securities (at the end of Mar. 2017) Approx. JPY 109.6bn

Operational investment securities and other investment securities held are quarterly evaluated through fair value, and the calculated number above reflects the <u>fair value of SBIH's ownership</u>

(ii) Value of SBI Investment (based on the closing price of Apr. 27, 2017)

(* Valuation excluding assets such as securities hold) Approx. JPY 18.4bn

Calculated according to the Comparable Public Company Analysis

Compares the market cap and profit of the comparable public company, JAFCO

Provisional amount of SBI Investment's net income that represents the actual status deducting expenses produced relevant to the holding company function held by it × JAFCO's PER (*)

The estimated net income per share used in the calculation is the average between that of Japanese company handbook and Nikkei Kaisha Joho.

^{*}PER of JAFCO is calculated by the estimated net income per share for FY2017.



Valuation by Segment Estimated by SBIH (2) Asset Management Business - ②

(iii) Value of SBI SAVINGS BANK (based on the closing price of Apr. 27, 2017)

Estimates the valuation of SBI SAVINGS BANK at <u>JPY</u>

<u>76.4bn</u> → <u>JPY 75.6bn</u>

(Shareholding of the SBI Group: 99.0%)

Estimation of the valuation is as follows:

Calculated according to the Comparable Public Company Analysis

Compares the asset sizes of comparable public companies, including savings banks and local banks in Korea

X

Median value of PBR of listed savings banks and local banks in Korea*1

Balance of SBI SAVINGS BANK's substantive equity*2
(As of the end of Mar. 2017)

^{*1} PBR of listed savings banks and local banks in Korea is calculated by recent equity per share

^{*2} Balance of substantive equity is the SBI Savings Bank's equity considering goodwill

^{*3} SBI's shareholding percentage corresponds to a figure based on the IFRS criteria that excludes a percentage of outside shareholder's interest of subsidiary companies and subsidiary funds of the Group.

Valuation by Segment Estimated by SBIH (2) Asset Management Business- ③



(iv) Total market cap of listed subsidiaries and equity method associates

	SBI's share- holding pct. (%)	Classification	Listed market	Market cap (JPY billion)	SBI's equity interest of market cap (JPY billion)
Morningstar Japan	49.6	Consolidated subsidiary	TSE JASDAQ	26.2	13.0
SBI Investment KOREA	43.9	Equity method associate	KOSDAQ of KRX	10.8*	4.8
Sum of the market cap	of a listed subsidiar	y and an equity r	method associate	37.0	<u>17.8</u>

(Based on the closing price of Apr. 27, 2017. *Calculated by the exchange rate as of Apr. 27, 2017.)

[Other profitable businesses of the Asset Management Business that are not included in the above valuation]

	Business lineup	Profit before income tax expense for FY2016 (JPY billion)	SBI's shareholding pct. (%)
SBI Estate Finance	Real estate secured loans	0.4	100.0

^{*} SBI's shareholding percentage corresponds to a figure based on the IFRS criteria that excludes a percentage of outside shareholder's interest of subsidiary companies and subsidiary funds of the Group.

Valuation by Segment Estimated by SBIH (3) Biotechnology-related Business



Biotechnology-related Business

Each bioventure company has multiple promising pipelines, and the Biotechnology-related Business will become a core business that makes a substantial contribution through progress in areas including pharmaceutical clinical research in Japan and overseas.

Total valuation of the Biotechnology-related Business is estimated at approx.JPY88.4bn

1 SBI Pharmaceuticals

Estimation of the valuation is as follows:

Market value at the point of partial transference of former SBI ALApromo's shares

Number of shares issued

SBIH's equity interest (excluding external holdings)

Based on SBIH's equity interest (84.9%; excluding external holdings) as of the end of Mar. 2017, the amount is calculated to be <u>approx. JPY 63.7bn</u>

② Kubota Pharmaceutical HD

	SBI's share- holding pct. (%)	Classification	Listed market	Market cap (JPY billion) (as of Apr. 27, 2017)	SBI's equity interest of market cap (JPY billion)
Kubota Pharmaceutical HD	38.2	Equity method associate	TSE Mothers	27.0	10.3

③ SBI Biotech (SBI's shareholding percentage*: 87.6%)
Estimated value based on SBIH's shareholding of paid-in capital

^{*} SBI's shareholding percentage corresponds to a figure based on the IFRS criteria that excludes a percentage of outside shareholder's interest of subsidiary companies and subsidiary funds of the Group.



(2) The Asset Management Business' Financial Information by Segment and Assets Under Management



Analysis of Each Segment of the Asset Management Business Holdings - 1 Private equity investment-

[Consolidated statement of financial position]

(IFRS; JPY billion)

(IFKS, JET DIIII		
	Mar. 31, 2016	Mar. 31, 2017
Cash and cash equivalents	22.2	35.0
Securities	120.0	113.9
Other assets	19.0	10.1
Total assets	161.2	159.0
Intragroup borrowings	15.1	30.8
Other liabilities	8.8	12.6
Total liabilities	23.9	43.4
Equity capital equivalent	93.8	87.4
Non-controlling interests* ¹ (Mainly interests of external shareholders of consolidated funds)	43.5	28.2
Total equity	137.3	115.6
Total liabilities and equity	161.2	159.0

- Securities held, whether listed or unlisted, are assessed at fair value.
- Non-consolidated funds are assessed at fair value, and only the amount corresponding to the Company's interest is recognized.
- For this reason, the amount of non-controlling interests (outside equity interests) is small.

[Consolidated statement of income]

(IFRS; JPY billion)

·	•	
	FY2015	FY2016
Revenue	18.8	10.7
Profit / loss related to FVTPL	16.2	6.9
Fee from non-cons. funds*	0.7	0.5
Others (FX gain etc.)	1.9	3.3
Expense (including expense related to allowance etc.)	(7.1)	(6.6)
Profit before income tax expense	11.7	4.1
Profit for the period	8.1	(0.7)
Attributable to owners of SBIH	4.8	(0.2)
Non-controlling interests	3.3	(0.5)

Only the amount of management commissions, etc. from funds classified as investment securities is recorded as income corresponding to external investors' shareholding

 Marketable securities account for approximately 40% of overall consolidation (the rest is SBI SAVINGS Bank, SBI Life Insurance, etc.) and nearly all of the profits or losses are recognized upon the change in fair value as FVTPL.

Reference: ② Consolidated subsidiaries among the companies acquired to manage and consult





-2 Consolidated subsidiaries among the companies acquired to manage and consult-

[Consolidated statement of financial position]

(IFRS; JPY billion)

	Mar. 31, 2016	Mar. 31, 2017
Cash and cash equivalents	5.3	1.8
Trade accounts receivable	15.6	14.9
Inventories (products)	2.8	0.0
Intangible assets	6.3	4.6
Other assets	7.1	1.5
Total assets	37.1	22.8
Total liabilities	18.4	12.3
Equity capital equivalent	18.3	10.4
Non-controlling interests	0.4	0.1
Total equity	18.7	10.5
Total liabilities and equity	37.1	22.8

[Consolidated subsidiaries]

- SBI Estate Finance (formally CEM Corporation)
- (Real estate-secured loans)
- NARUMIYA INTERNATIONAL (apparel company)

[Consolidated statement of income]

(IFRS; JPY billion)

	FY2015	FY2016
Revenue	3.6	4.1
Profit before income tax expense	1.2	1.4
Profit for the period	0.8	0.9
Attributable to owners of SBIH	0.4	0.4
Non-controlling interests	0.4	0.5

- Whereas all of investees are uniformly consolidated under IFRS, there is an exclusion rule under J-GAAP.
- Although the accounting treatment under IFRS differs from J-GAAP, the impact on the Company's consolidated financial statements is insignificant.
 - * SBI AXES, an operational investee company, was classified as a affiliate within the Asset Management Business, but was transferred to the Financial Services Business. The FY2015 results are adjusted retroactively, assuming that SBI AXES was a component of the Asset Management Business from the beginning of FY2015.

Reference: 3 Overseas financial services business



Analysis of Each Segment of the Asset Management Business Holdings - 3 Overseas financial services business-

[Consolidated statement of financial position]

(IFRS; JPY billion)

	Mar. 31, 2016	Mar. 31, 2017
Cash and cash equivalents	38.6	47.4
Trade accounts receivable	331.5	436.5
Intangible assets	112.2	110.9
Other assets	60.7	54.5
Total assets	543.0	649.3
Customer deposits	386.0	485.8
Other liabilities	10.4	11.1
Total liabilities	396.4	496.9
Equity capital equivalent	145.8	151.4
Non-controlling interests	0.8	1.0
Total equity	146.6	152.4
Total liabilities and equity	543.0	649.3

[Consolidated subsidiaries]

 SBI SAVINGS Bank (Korea) and SBI Royal Securities (Cambodia)

[affiliates to which the equity method]

 SBI Thai Online Securities (Thailand) and YAR Bank (Russia)

[Consolidated statement of income]

(IFRS; JPY billion)

	FY2015	FY2016
Revenue	43.2	52.2
Profit before income tax expense	4.6	6.1
Profit for the period	5.2	7.0
Attributable to owners of SBIH	5.1	6.9
Non-controlling interests	0.1	0.1

- The results of SBI SAVINGS Bank (Korea) are primarily reflected in the financial statements.
- Net interest income, which reflects the earnings of the loan business, equivalent to the difference between interest income from operational loan receivables and interest cost for the customer deposits, resulted JPY 34.6bn (increase of 36.9% YoY) for FY2016, steadily strengthening of the revenue base.

Reference: 4 Asset management services business



[Consolidated statement of financial position]

(IFRS; JPY billion)

	Mar. 31, 2016	Mar. 31, 2017
Cash and cash equivalents	7.8	5.0
Financial assets	0.8	0.9
Intangible assets	4.1	4.2
Other assets	0.7	4.6
Total assets	13.4	14.7
Total liabilities	0.9	1.1
Equity capital equivalent	8.2	9.1
Non-controlling interests	4.3	4.5
Total equity	12.5	13.6
Total liabilities and equity	13.4	14.7

- Morningstar Japan and its subsidiaries are the main constituent companies
- Planning the establishment of SBI Global Asset Management as an intermediate holding company of the business

[Consolidated statement of income]

(IFRS; JPY billion)

	FY2015	FY2016
Revenue	4.1	4.3
Profit before income tax expense	1.4	1.4
Profit for the period	0.9	0.6
Attributable to owners of SBIH	0.4	0.2
Non-controlling interests	0.5	0.4

- The results of Morningstar Japan are primarily reflected in the financial statements.
- With the establishment of SBI Global Asset Management, the Group's asset management operations are expected to be strengthened

Assets Under Management of the SBI Group



(As of the end of Mar. 2017)

Private equity, etc. JPY 253.7bn (Including JPY 106.1bn of both cash and commitment amount to be paid in) (*3)

Breakdown by Industry	Amount
IT/Internet	38.0
Biotechnology/Health/Medical	15.0
Services	10.8
Materials/Chemicals	1.4
Environmental/Energy	13.9
Retail/Food	8.9
Construction/Real estate	1.0
Machine/Automobile	6.2
Finance	37.5
Others	14.9
Total	147.6

Breakdown by region	Amount	
Japan	51.4	
China	20.6	
Korea	33.2	
Taiwan	1.0	
Southeast Asia	8.7	
India	5.7	
U.S.	20.8	
Others	6.1	
Total	147.6	


Investment trusts, etc.	JPY282.1bn (*4
Investment trusts	188.9
Investment advisory	88.6
Investment companies	4.6

- *1 Calculated by the exchange rate as of the end of Mar. 2017
- *2 Amounts are rounded to the nearest JPY 100m
- *3 Composed of cash in funds and unpaid capital which is to be paid on a capital call.
- *4 For funds that SBI Asset Management provides investment instruction to, if Morningstar Asset Management provides investment advisory services, assets are recorded in both "Investment trusts" and "Investment advisory," respectively, and such overlapping amounts totaled JPY 30bn



(3) State of the Group

The SBI Group's Customer Base, which was Expanded through the Thorough Pursuit of the Customer-centric Principle and Group Synergies



Mar. 2013 Mar. 2014 Mar. 2015 Mar. 2016 Mar. 2017

^{*1} The cases that customers who are not identified as the same person within each service website and overlapping customers among the Group companies are double counted.

^{*2} Owing to the reorganization, customer numbers of the Group companies, which were excluded from consolidation, are not included in the figures for the past customer bases.

^{*3} Includes the number of smartphone app downloads, as provided by Morningstar

^{*4} The total number of contracts of SBI Insurance excludes continuing contracts, expiring contracts and early-withdrawals.



Number of Companies and Consolidated Employees of the SBI Group

Number of Group companies

	Mar. 2013	Mar. 2014	Mar. 2015	Mar. 2016	Mar. 2017
Consolidated subsidiaries (companies)	144	139	142	147	166
Consolidated partnerships (partnerships)	34	36	31	31	21
Total consolidated subsidiaries(companies)	178	175	173	178	187
Equity method companies (companies)	38	38	39	33	36
Total Group companies (companies)	216	213	212	211	223

Number of consolidated employees

	Mar. 2013	Mar. 2014	Mar. 2015	Mar. 2016	Mar. 2017
Total employees (persons)	5,007	5,352	6,094	5,480	4,455*

^{*} Since NARUMIYA INTERNATIONAL was excluded from the Group, the number of employees decreased



http://www.sbigroup.co.jp/english/